{
  "meta": {
    "title": "Late_Night_Pyq_Inicet_Mixed_Bag-21",
    "url": "https://brainandscalpel.vercel.app/late-night-pyq-inicet-mixed-bag-21-6b022f36.html",
    "scrapedAt": "2025-11-29T18:11:24.369Z"
  },
  "questions": [
    {
      "id": 9908,
      "choices": [
        {
          "id": 39598,
          "text": "<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">2, 4</span></span></span></p>"
        },
        {
          "id": 39599,
          "text": "<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">1, 2, 3</span></span></span></p>"
        },
        {
          "id": 39600,
          "text": "<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">2, 3, 4</span></span></span></p>"
        },
        {
          "id": 39601,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">1, 2, 4</span></span></span></p>"
        }
      ],
      "text": "<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Blood examination shows pancytopenia, which can be correct? </span></span></span>(AIIMS NOV 2020)</p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Megaloblastic anemia </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Hairy cell leukemia </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">MDS with hypocellular BM </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">APML</span></span></span></li>\r\n</ol>",
      "unique_key": "Q9117173",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384525,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) 1, 2, 3</span></strong> </span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Megaloblastic anemia (hypocellular phase), hairy cell leukemia, and MDS (hypocellular bone marrow) can show pancytopenia. </span></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Megaloblastic anemia:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> This type of anemia, often caused by vitamin B12 or folate deficiency, can lead to pancytopenia, especially in its more severe or hypocellular phase. The bone marrow in megaloblastic anemia can show hypercellularity with ineffective hematopoiesis, but in some cases, it can present as hypocellular, contributing to pancytopenia.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hairy cell leukemia:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> This is a type of chronic B-cell lymphoproliferative disorder. It is commonly associated with pancytopenia due to bone marrow infiltration by hairy cells and associated fibrosis, which suppresses normal hematopoiesis.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">MDS with hypocellular BM:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> Myelodysplastic syndromes (MDS) are a group of hematologic conditions characterized by ineffective hematopoiesis and dysplasia in one or more of the myeloid cell lines. In cases of MDS with a hypocellular bone marrow, pancytopenia can occur due to the reduced production of blood cells.</span></span></span></li>\r\n</ol>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">4. Acute promyelocytic leukemia (APML)</span></strong><span style=\"font-size:12.0pt\"> is typically not associated with pancytopenia. APML usually presents with leukocytosis or normal white cell counts, along with thrombocytopenia and anemia. However, severe pancytopenia is not a characteristic feature, and therefore, APML is not typically associated with pancytopenia.</span></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Causes of pancytopenia &ndash; </span></strong></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">I. <strong>Aplastic anemia</strong> </span></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">II. <strong>Pancytopenia with normal or increased marrow cellularity e.g.</strong></span></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Myelodysplastic syndromes</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Hypersplenism</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Megaloblastic anemia</span></span></span></li>\r\n</ol>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">III<strong>. Paroxysmal nocturnal hemoglobinuria (page 314</strong>)</span></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">IV<strong>. Bone marrow infiltrations e.g.</strong></span></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Hematologic malignancies (<u>leukemias, lymphomas, myeloma</u>)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Non-hematologic metastatic malignancies</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Storage diseases</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Osteopetrosis</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Myelofibrosis</span></span></span></li>\r\n</ol>",
      "correct_choice_id": 39599,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11142,
      "choices": [
        {
          "id": 44534,
          "text": "<p><span style=\"font-size:18px;\">Screening of family members</span></p>"
        },
        {
          "id": 44535,
          "text": "<p><span style=\"font-size:18px;\">Mobilization of resources</span></p>"
        },
        {
          "id": 44536,
          "text": "<p><span style=\"font-size:18px;\">Social support</span></p>"
        },
        {
          "id": 44537,
          "text": "<p><span style=\"font-size:18px;\">Interpersonal therapy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:18px;\"><strong>Which of the following elements is not included in the provisions of the Mental Health Care Act of 2017, as per the WHO's mhGAP? </strong><i><strong>[AIIMS NOV 2018]</strong></i></span></p>",
      "unique_key": "Q2335178",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384530,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:18px;\"><strong>Ans. (a) Screening of family members</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:18px;\">The Mental Health Care Act, 2017 focuses on the rights and treatment of patients with mental illness, but it does not specifically include provisions for the screening of family members.</span></li><li><span style=\"font-size:18px;\">The Act covers various aspects such as the capacity to make healthcare decisions, advance directives, nominated representatives, types of admissions, bans on certain treatments (like direct ECT for minors and psychosurgery), decriminalization of suicide attempts, and regulations on restraints and seclusion.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>Option B. Mobilization of resources:</strong> The Act includes provisions related to the mobilization of resources for mental health services.</span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>Option C. Social support:</strong> Social support is a crucial aspect of mental health care covered under the Act, ensuring that patients receive necessary support from family and community.</span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>Option D. Interpersonal therapy:</strong> While specific therapies may not be explicitly listed, the Act does promote access to various mental health treatments, which can include interpersonal therapy.</span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:18px;\">Screening of family members is not included in the Mental Health Care Act, 2017.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>Additional Information</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>MENTAL HEALTHCARE ACT, 2017 (MHCA 2017)</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:18px;\">Deals with rights of patients with mental illness and treatment delivery. Important clauses-</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:18px;\">A. Capacity to make mental healthcare and treatment decision- Every person, including patients with mental illness, are assumed to have it if they can-</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:18px;\">Can understand the information provided to them</span></li><li><span style=\"font-size:18px;\">Understand the consequences of their decisions</span></li><li><span style=\"font-size:18px;\">Can communicate their decision</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:18px;\">B. Advance directive- Every person (not a minor) can make an advance directive in which he can mention-</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:18px;\">How they wish to be treated/not treated for a mental illness</span></li><li><span style=\"font-size:18px;\">Applicable only if a person loses the capacity to take mental healthcare or treatment decisions</span></li><li><span style=\"font-size:18px;\">Duty of psychiatrist (or medical officer) to give treatment according to the advance directive</span></li><li><span style=\"font-size:18px;\">Doctor is not liable in case of unforeseen consequences while following the advance directive</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:18px;\">C. Nominated representative (NR)-</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:18px;\">Every person can appoint a nominated representative</span></li><li><span style=\"font-size:18px;\">In case of loss of capacity to make mental healthcare and treatment decision, NR would help in taking decisions about treatment</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:18px;\">D. Admission- MHCA 2017 allows two types of admissions</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:18px;\">Independent admissions- When the patient himself wants to get admitted</span></li><li><span style=\"font-size:18px;\">Supported admission (for a maximum of 30 days)- A person who has lost the capacity to make mental healthcare or treatment decisions and requires significant support from a nominated representative can be admitted under a “supported admission”</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:18px;\">E. Ban on direct ECT</span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\">F. Ban on ECT for minors</span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\">G. Ban on psychosurgery</span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\">H. Decriminalisation of suicide attempt - Any person who attempts suicide shall be presumed to be under severe stress and should not be tried or punished</span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\">I. Restraints and seclusions - A patient can be physically restrained only-</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:18px;\">If it is the only way to prevent harm to self or others</span></li><li><span style=\"font-size:18px;\">If authorised by a psychiatrist in charge</span></li></ul>",
      "correct_choice_id": 44534,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 23232,
      "choices": [
        {
          "id": 92892,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">5 alpha reductase deficiency </span></span></span></p>"
        },
        {
          "id": 92893,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">17 alpha hydroxylase deficiency </span></span></span></p>"
        },
        {
          "id": 92894,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Androgen insensitivity syndrome </span></span></span></p>"
        },
        {
          "id": 92895,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Swyer syndrome</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 15-year-old girl comes in with primary amenorrhea and indications of virilization. She displays underdeveloped breasts and pubic hair consistent with prepubertal stages, rated at Tanner stage 2. She has a closed-off vaginal canal and noticeable enlargement of the clitoris. Despite her female sex, her testosterone levels are within the male range. Her genetic makeup is 46XY. What is the likely medical diagnosis in this case?&nbsp;</span></span>(INICET MAY 2023)</p>",
      "unique_key": "Q9146024",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384458,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) 5 alpha reductase deficiency </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The given scenario points to a diagnosis of 5 alpha reductase deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">5 alpha reductase deficiency causes inability to convert testosterone to DHT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When DHT levels are low, newborns will possess external genitalia with a feminine appearance. These youngsters are commonly brought up as girls until they reach puberty, at which point they begin to display signs of masculinization due to the influence of testosterone. As a result, clitoromegaly becomes evident. The absence of estrogen conversion from testosterone results in limited breast growth. Scanty pubic hair is observed since its growth is contingent on both testosterone and dihydrotestosterone.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/15/whatsapp-image-2023-06-12-at-190121011010201026_page_49.jpg\" style=\"height:533px; width:700px\" /></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. 17 alpha hydroxylase deficiency</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Leads to reduced formation of corticosteroids, sex hormones and increased mineralocorticoids (causing hypokalemia and hypertension). Patient with XY chromosome presents with atypical genitalia and undescended testes. Patient with XX chromosome lacks secondary sexual development.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Androgen insensitivity syndrome</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Defect in androgen receptor resulting in female-appearing genetic male (46, XY); female external genitalia with scant axillary and pubic hair, rudimentary vagina; uterus and fallopian tubes absent due to persistence of anti-Mullerian hormone from testes. Patients develop normal functioning testes. Patient has increased testosterone, estrogen &amp; LH as compared to other sex chromosome disorders.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Swyer syndrome</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: 46 XY gonadal dysgenesis; Absent secondary sexual characters, but normal female internal and external genitalia. Gonadectomy needs to be done.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">5-alpha reductase deficiency causes primary amenorrhea and virilization in genetic females (46XY), resulting in the inability to convert testosterone to dihydrotestosterone (DHT). This leads to female external genitalia at birth and masculinization at puberty, with signs such as clitoromegaly and underdeveloped breasts.</span></span></span></p>",
      "correct_choice_id": 92892,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13019,
      "choices": [
        {
          "id": 52038,
          "text": "<p><span style=\"font-size:12.0pt;\">Durham's rule</span></p>"
        },
        {
          "id": 52039,
          "text": "<p><span style=\"font-size:12.0pt;\">Curren's rule</span></p>"
        },
        {
          "id": 52040,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Both A and B</span></p>"
        },
        {
          "id": 52041,
          "text": "<p><span style=\"font-size:12.0pt;\">Neither A nor B</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Identify the rules used as tests of insanity? (</span>INICET Nov 2021)</p>",
      "unique_key": "Q6387994",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384493,
      "difficulty_level": "beginner",
      "subjects_id": [
        10
      ],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ans. C. Both A and B</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Durham's rule and Curren's rule are used in cases as tests for insanity.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"background-color:white;color:#202124;font-size:12.0pt;\">The Durham's rule states, “<strong>an accused is not criminally responsible if his unlawful act was the product of mental disease or mental defect</strong>”.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">The Curren's rule states that “an accused person will not be criminally responsible, if at the time of committing the act, he did not have the capacity to regulate his conduct to the requirements of law, as a result of mental disease or defect”.</span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12pt;\">Both Durham's rule and Curren's rule are significant tests used to determine criminal responsibility in cases where the defendant's mental state is in question.</span></p>",
      "correct_choice_id": 52040,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7005,
      "choices": [
        {
          "id": 27988,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">1.8</span></span></span></p>"
        },
        {
          "id": 27989,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">10</span></span></span></p>"
        },
        {
          "id": 27990,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">14</span></span></span></p>"
        },
        {
          "id": 27991,
          "text": "<p><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">18</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A drug solution containing 500 mg/5 ml of the drug is given to you. You are provided with a 2 ml syringe (having 10 divisions for each mI). How many divisions of the 2 m syringe need to be administered to deliver 180 mg of the drug to a patient? (</span></span></span>AIIMS May 2018)</p>",
      "unique_key": "Q9197548",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384526,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D. 18</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">500 mg of the drug is present in 5ml of the solution.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Therefore, 180 mg will be present in (5/500) *180 = 1.8ml</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In the syringe provided, 1ml = 10 divisions,</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Therefore 1.8ml = 18 divisions.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">To deliver 180 mg of the drug using the provided 2 ml syringe with 10 divisions per ml, you need to fill the syringe to 18 divisions.</span></span></span></p>",
      "correct_choice_id": 27991,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2460,
      "choices": [
        {
          "id": 9826,
          "text": "<p><span style=\"font-size:12.0pt;\">0.7</span></p>"
        },
        {
          "id": 9827,
          "text": "<p><span style=\"font-size:12.0pt;\">0.8</span></p>"
        },
        {
          "id": 9828,
          "text": "<p><span style=\"font-size:12.0pt;\">1</span></p>"
        },
        {
          "id": 9829,
          "text": "<p><span style=\"font-size:12.0pt;\">1.2</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What would be the respiratory quotient if someone is on an exclusive carbohydrate diet? (</span>AIIMS Nov 2018)</p>",
      "unique_key": "Q7702949",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384461,
      "difficulty_level": "beginner",
      "subjects_id": [
        1
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) 1</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The respiratory quotient (RQ) is defined as the ratio of the volume of CO2 produced to the volume of O2 consumed during metabolism. The RQ value varies depending on the type of substrate being metabolized.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Respiratory Quotient Values of Carbohydrates:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The RQ for carbohydrates is 1. This is because the metabolism of carbohydrates involves the complete oxidation of glucose, which produces CO2 and consumes O2 in a 1:1 ratio. The equation for glucose oxidation is:</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">When an individual is on an exclusive carbohydrate diet, the metabolism of carbohydrates is the primary source of energy, leading to an RQ value of 1. In conditions like diabetes mellitus, where the utilization of carbohydrates is impaired and fat metabolism predominates, the RQ falls below 1.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Respiratory quotient (RQ) is defined as the <strong>ratio of volume of CO<sub>2</sub> produced in L/g to the oxygen consumed in L/g.</strong></span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/06/03_GMxc2Ks.jpg\" alt=\"\" width=\"1000\" height=\"377\"></p>",
      "correct_choice_id": 9828,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11430,
      "choices": [
        {
          "id": 45686,
          "text": "<p><span style=\"font-size:12.0pt;\">Aspartate aminotransferases /platelet ratio</span></p>"
        },
        {
          "id": 45687,
          "text": "<p><span style=\"font-size:12.0pt;\">Fibro test</span></p>"
        },
        {
          "id": 45688,
          "text": "<p><span style=\"font-size:12.0pt;\">Forns index</span></p>"
        },
        {
          "id": 45689,
          "text": "<p><span style=\"font-size:12.0pt;\">Serum laminin &amp; serum hyaluronidase</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Noninvasive test to detect hepatic fibrosis include?</span><span style=\"color:black;font-size:12.0pt;\"> (AIIMS MAY 2017)</span></p>",
      "unique_key": "Q8240132",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384516,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Fibro test</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The FibroTest, also known as the Fibro test, is a noninvasive, blood-based test designed specifically to detect hepatic fibrosis. This test calculates the degree of liver fibrosis using a combination of several serum biochemical markers including haptoglobin, bilirubin, gamma-glutamyl transpeptidase (GGT), apolipoprotein A1, and alpha-2 macroglobulin. It evaluates liver damage and fibrosis by measuring these markers, which are affected by liver function and architecture changes.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Aspartate aminotransferases /platelet ratio (APRI):</strong> Incorrect as it is primarily used to estimate the likelihood or severity of fibrosis rather than to directly detect it. It correlates with the degree of liver fibrosis but is less specific.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Forns index:</strong> Incorrect for the same reason as APRI. The Forns index is used to assess the risk of developing liver fibrosis based on variables including age, platelet count, cholesterol levels, and GGT, but it does not directly measure fibrosis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Serum laminin &amp; serum hyaluronidase:</strong> Incorrect as these are not standard tests for directly detecting hepatic fibrosis; they can indicate changes in extracellular matrix turnover but are less specific and commonly used compared to the FibroTest.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Fibro test is a sensitive test to detect hepatic fibrosis. It is a <strong>multiparameter blood test</strong> which incorporate haptoglobin, bilirubin, GGT, apolipoprotein A1, and alpha-2 macroglobulin.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Test for estimating risk developing hepatic fibrosis:</strong></span></p><p>&nbsp;</p><ol style=\"list-style-type:lower-alpha;\"><li><span style=\"font-size:12.0pt;\">AST/platelet ratio</span></li><li><span style=\"font-size:12.0pt;\">Forns index</span></li><li><span style=\"font-size:12.0pt;\">Fib-4</span></li><li><span style=\"font-size:12.0pt;\">Cirrhosis determinant score.</span></li></ol><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Test for detecting hepatic fibrosis: <strong>Fibro test</strong>.</span></p>",
      "correct_choice_id": 45687,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10123,
      "choices": [
        {
          "id": 40458,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bedside blood collection, label the samples, fill the laboratory requisition forms, Identify the patient</span></span></span></p>"
        },
        {
          "id": 40459,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fill the laboratory requisition forms, Identify the Patient, Bedside blood collection, label the samples</span></span></span></p>"
        },
        {
          "id": 40460,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Label the sample tubes, Bedside blood collection, fill the laboratory requisition forms, Identify the patient</span></span></span></p>"
        },
        {
          "id": 40461,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Identify the Patient, Fill the laboratory requisition forms, Bedside blood collection, label the samples</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:left\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Identify the correct sequence: </span></span>(AIIMS MAY 2017)</p>",
      "unique_key": "Q5795264",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384528,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12pt\"><strong>Ans. B)</strong>&nbsp;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Fill the laboratory requisition forms, Identify the Patient, Bedside blood collection, label the samples</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The correct sequence for blood collection and sample handling in a clinical setting involves several critical steps to ensure patient safety and accurate test results. The sequence is as follows:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Provisional diagnosis by the physician</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: This initial step involves the physician evaluating the patient and determining the necessary diagnostic tests.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Fill the laboratory requisition forms</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: The healthcare staff or laboratory personnel must fill out the requisition forms based on the physician&#39;s diagnosis. This step is crucial because it ensures that the correct tests are requested and that the laboratory has all the necessary information to process the samples.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Identify the Patient</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: Before collecting any samples, the healthcare staff must properly identify the patient. This step is vital to prevent any mix-up of samples, which could lead to incorrect diagnosis and treatment.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Bedside blood collection</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: After confirming the patient&#39;s identity, the blood sample is collected at the bedside. Proper collection technique is essential to avoid contamination or sample degradation.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Label the samples</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: Finally, the collected samples must be labeled accurately and immediately to ensure that they are correctly matched with the patient and the requested tests.</span></span></span></li>\r\n</ol>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">This sequence ensures that the right patient receives the correct test, and the results are reliable and accurate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Sequence:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Provisional diagnosis by the physician &gt; Requisition forms are filled accordingly for test to the lab &gt; patient is identified by the laboratory personnel/ health care staff &gt; samples are collected and labeled appropriately.</span></span></span></p>",
      "correct_choice_id": 40459,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "CriteriaBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 74866,
      "choices": [
        {
          "id": 298365,
          "text": "<p><span style=\"font-size:16px;\">R.O.P</span></p>"
        },
        {
          "id": 298366,
          "text": "<p><span style=\"font-size:16px;\">Congenital Cataract</span></p>"
        },
        {
          "id": 298367,
          "text": "<p><span style=\"font-size:16px;\">Retinoblastoma</span></p>"
        },
        {
          "id": 298368,
          "text": "<p><span style=\"font-size:16px;\">Coat’s Disease</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:16px;\">A 1-year-old child who was born premature at 34 weeks POG weighing 1400 gms presents with leukocoria. On CT, intraocular calcification is seen. What is the most probable diagnosis? (INICET NOV 2024)</span></p>",
      "unique_key": "Q8894049",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384460,
      "difficulty_level": "intermediate",
      "subjects_id": [
        8
      ],
      "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. C) Retinoblastoma</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">While the history of prematurity (34 weeks) and low birth weight (1400g) might suggest ROP, the presence of intraocular calcification on CT scan is pathognomonic for retinoblastoma. Retinoblastoma is the most common primary intraocular malignancy of childhood, and it is the only condition among the given options that shows intraocular calcification. This calcification can be detected on CT scan, though CT is generally avoided due to radiation exposure risks. The preferred imaging modalities are ultrasound B-scan and contrast-enhanced MRI.</span><br><br><span style=\"font-size:16px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-03-20%20115715.jpg\" width=\"612\" height=\"330\"></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option A. ROP (Retinopathy of Prematurity):&nbsp;</strong>While the premature birth and low birth weight are risk factors for ROP, it does not present with intraocular calcification. ROP occurs in newborns &lt;34 weeks or &lt;2.0 kg birth weight and presents with abnormal vessel development.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option B. Congenital Cataract:&nbsp;</strong>This presents as leukocoria but does not show intraocular calcification. It is an opacity of the natural lens that is present at birth.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option D. Coat's Disease:&nbsp;</strong>While this can present with leukocoria, it is characterized by retinal telangiectasia and exudation without calcification. It typically affects young males and is usually unilateral.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">Intraocular calcification seen on imaging in a child with leukocoria is pathognomonic for retinoblastoma, regardless of other clinical factors like prematurity.</span></p>",
      "correct_choice_id": 298367,
      "solution_audio": null,
      "solution_video": "https://media.cerebellumacademy.com/media/public/question_media/solution/video/74866/INI-CET_Nov_2024_Opthalmolgy_Q_-_3.mp4",
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "top",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": "https://media.cerebellumacademy.com/media/public/question_media/solution/video/74866/INI-CET_Nov_2024_Opthalmolgy_Q_-_3.mp4",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54298,
      "choices": [
        {
          "id": 216661,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">NREM1</span></span></span></p>"
        },
        {
          "id": 216662,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">NREM2</span></span></span></p>"
        },
        {
          "id": 216663,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">NREM3</span></span></span></p>"
        },
        {
          "id": 216664,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">REM</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">&nbsp;Identify the stage of sleep based on the EEG shown below:</span></span></span>&nbsp;(INICET MAY 2024)</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/22/screenshot-2024-08-22-131403.jpg\" style=\"height:246px; width:500px\" /></span></span></span></p>",
      "unique_key": "Q7209268",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384504,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> <strong>D) REM</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The EEG provided shows a pattern that mimics an awake state, which is indicative of REM (Rapid Eye Movement) sleep. REM sleep is characterized by specific EEG, EOG (electro-oculogram), and EMG (electromyogram) patterns:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">EEG (Electroencephalogram):</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> During REM sleep, the EEG shows low amplitude, mixed frequency activity that resembles the awake state. This is in contrast to the high amplitude, low-frequency waves seen in NREM (Non-Rapid Eye Movement) sleep stages.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">EOG (Electro-oculogram):</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> The EOG shows rapid eye movements, which are characteristic of REM sleep. These movements are visible as sharp spikes or fluctuations in the EOG tracing.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">EMG (Electromyogram):</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> The EMG shows muscle atonia or paralysis, which is another hallmark of REM sleep. This paralysis prevents the sleeper from acting out their dreams. Only the diaphragm and extraocular muscles remain active during REM sleep.</span></span></span></li>\r\n</ol>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A. NREM1:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> This is the lightest stage of sleep, characterized by a transition from wakefulness to sleep. The EEG shows a mix of alpha and theta waves, with some slow eye movements, but it does not resemble the awake state as closely as REM sleep does.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B. NREM2:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> This stage is marked by sleep spindles and K-complexes on the EEG. It is a deeper stage of sleep than NREM1 but does not show the rapid eye movements or muscle atonia seen in REM sleep.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C. NREM3:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> Also known as slow-wave sleep (SWS), this stage is characterized by high amplitude, low-frequency delta waves on the EEG. It is the deepest stage of NREM sleep and does not resemble the awake state.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">REM sleep is characterized by EEG patterns similar to wakefulness, rapid eye movements on EOG, and muscle atonia on EMG.</span></span></span></p>",
      "correct_choice_id": 216664,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "ImageBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 43600,
      "choices": [
        {
          "id": 174063,
          "text": "<p><span style=\"font-size:12.0pt;\">Tc Sestamibi scan</span></p>"
        },
        {
          "id": 174064,
          "text": "<p><span style=\"font-size:12.0pt;\">Tc Sestamibi SPECT</span></p>"
        },
        {
          "id": 174065,
          "text": "<p><span style=\"font-size:12.0pt;\">USG</span></p>"
        },
        {
          "id": 174066,
          "text": "<p><span style=\"font-size:12.0pt;\">MRI</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What is the most sensitive investigation for parathyroid tumor imaging?</span>(INICET NOV 2023)</p>",
      "unique_key": "Q2142216",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384509,
      "difficulty_level": "beginner",
      "subjects_id": [
        17
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Tc Sestamibi SPECT</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">For the imaging of parathyroid tumors, particularly in the context of hyperparathyroidism, several modalities can be employed. Each has its strengths and particular clinical situations where it might be the preferred choice.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Tc Sestamibi SPECT (Single Photon Emission Computed Tomography </strong>technique also utilizes Technetium-99m sestamibi but combines it with CT imaging to provide three-dimensional imaging. This makes SPECT more sensitive than a plain sestamibi scan for locating parathyroid tumors, especially when they are ectopic or embedded deep within the neck or chest.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A.&nbsp;Tc Sestamibi Scan</strong>: This is a nuclear medicine scan that uses a small amount of a radioactive compound , typically Technetium-99m sestamibi, which is absorbed by active parathyroid tissue more than normal tissue. While sensitive, it provides a two-dimensional view which can sometimes make precise localization of smaller or deeper tumors challenging.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C.&nbsp;USG (Ultrasound):</strong> Ultrasound is useful for imaging the parathyroid glands due to its non-invasive nature and ability to detect lesions in real-time. It is particularly effective for glands located in typical positions near the thyroid. However, its effectiveness diminishes for ectopic glands or in obese patients where acoustic windows may be poor.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D.&nbsp;MRI (Magnetic Resonance Imaging):</strong> MRI can provide detailed images and is useful in complex cases, such as when other imaging modalities fail or in surgical planning. However, its sensitivity is generally lower than Sestamibi SPECT for detecting parathyroid adenomas, and it is less commonly used primarily due to higher costs and limited availability.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective</strong>:</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Tc Sestamibi SPECT is generally considered the most sensitive imaging modality for detecting parathyroid tumors, particularly because it offers three-dimensional localization capabilities that can greatly assist surgeons in planning minimally invasive surgery.</span></p>",
      "correct_choice_id": 174064,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10497,
      "choices": [
        {
          "id": 41954,
          "text": "<p><span style=\"font-size:12.0pt;\">Enzyme degradation</span></p>"
        },
        {
          "id": 41955,
          "text": "<p><span style=\"font-size:12.0pt;\">Type 4 hypersensitivity reaction</span></p>"
        },
        {
          "id": 41956,
          "text": "<p><span style=\"font-size:12.0pt;\">Fibrinoid deposition</span></p>"
        },
        {
          "id": 41957,
          "text": "<p><span style=\"font-size:12.0pt;\">Sudden cut-off of blood supply</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 42-year-old female patient presents with cough, low-grade fever, and hemoptysis. Investigations reveal a cavitary lesion on her right lung apex, which on biopsy reveals caseous necrosis. The underlying pathophysiology is: (AIIMS NOV 2021)</span></p>",
      "unique_key": "Q8377908",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384494,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Type 4 hypersensitivity reaction</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The clinical scenario with complaints of cough, low-grade fever, hemoptysis is suggestive of <strong>pulmonary tuberculosis</strong>. The diagnosis is further supported by a cavitary lesion in the apex of the lung and a biopsy showing caseous necrosis. The pathophysiology is a <strong>type 4 hypersensitivity</strong> reaction mediated by activated macrophages.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Tuberculosis is a chronic pulmonary and systemic disease caused by Mycobacterium tuberculosis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">With certain persistent or nondegradable antigens, such as tubercle bacilli colonizing the lungs or other tissues, the perivascular infiltrate is dominated by macrophages over a period of 2 or 3 weeks. The activated macrophages often undergo a morphologic transformation into epithelium-like cells and are then referred to as epithelioid cells. A microscopic aggregation of epithelioid cells, usually surrounded by a collar of lymphocytes, is referred to as a granuloma. This pattern of inflammation, called granulomatous inflammation, is typically associated with strong T-cell activation with cytokine production. It can also be caused by foreign bodies that activate macrophages without eliciting an adaptive immune response.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/14/untitled-404.jpg\" alt=\"\" width=\"500\" height=\"579\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Enzyme degradation</strong>: This does occur in TB but is not the primary mechanism leading to the granulomatous response and caseous necrosis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Fibrinoid deposition</strong>: This is typically associated with immune complex-mediated conditions, not TB.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Sudden cut-off of blood supply</strong>: This would more likely result in coagulative necrosis, not the caseous necrosis seen in TB.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Pulmonary tuberculosis&nbsp;</strong>is characterized by granulomatous inflammation with caseous necrosis, driven by a <strong>type 4 hypersensitivity reaction</strong> mediated by activated macrophages and T-helper cells.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Ref: Robbins pathologic basis of disease 8<sup>th</sup> edition pg 392</strong></span></p>",
      "correct_choice_id": 41955,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5893,
      "choices": [
        {
          "id": 23542,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibit implantation</span></span></span></p>"
        },
        {
          "id": 23543,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cervical mucus thickening</span></span></span></p>"
        },
        {
          "id": 23544,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibit ovulation</span></span></span></p>"
        },
        {
          "id": 23545,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increase GnRH release</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oral contraceptives act by all of the following mechanisms except:&nbsp;</span></span>(INICET NOV 2020)</p>",
      "unique_key": "Q6471954",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384464,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Increase GnRH release</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oral contraceptive pills (OCPs) function through several mechanisms to prevent pregnancy, but increasing the release of Gonadotropin-Releasing Hormone (GnRH) is not one of them. In fact, OCPs inhibit the release of GnRH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mechanisms of action of OCPs:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibit ovulation:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> By suppressing the release of GnRH, and consequently, the pituitary secretion of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH), OCPs prevent the development and release of an ovum.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prevent implantation:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> OCPs create a less favorable endometrial environment for implantation of a fertilized egg.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cervical mucus thickening:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> OCPs increase the viscosity of cervical mucus, making it more difficult for sperm to enter the uterus and fertilize an ovum.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Produce static endometrial hypoplasia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> OCPs cause the endometrial lining to remain thin, which further prevents implantation.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Affect tubal motility:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> OCPs can alter the motility of the fallopian tubes, reducing the likelihood of sperm meeting an ovum.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Inhibit implantation:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> OCPs prevent the endometrium from becoming suitable for implantation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Cervical mucus thickening:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> OCPs increase the thickness of cervical mucus to block sperm penetration.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Inhibit ovulation:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> OCPs suppress the hormonal signals that trigger ovulation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oral contraceptive pills prevent pregnancy by inhibiting ovulation, preventing implantation, thickening cervical mucus, producing static endometrial hypoplasia, and affecting tubal motility. They do not increase GnRH release; rather, they inhibit it.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Dutta&rsquo;s textbook of Gynecology 6<sup>th</sup> edition 485</span></strong></span></span></p>",
      "correct_choice_id": 23545,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7183,
      "choices": [
        {
          "id": 28700,
          "text": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tocainide</span></span></span></span></span></p>"
        },
        {
          "id": 28701,
          "text": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Propranolol</span></span></span></span></span></p>"
        },
        {
          "id": 28702,
          "text": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\">﻿﻿﻿<span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Quinidine</span></span></span></span></span></p>"
        },
        {
          "id": 28703,
          "text": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Lignocaine</span></span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An anti-arrhythmic drug, which is effective in both atrial and ventricular arrhythmias, is shown to have the following effect on action potential. Which of the following is the most likely drug? (</span></span></span></span>INICET Nov 2022)</p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-family:Helvetica\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/06/pharmc-1-10.jpg\" style=\"height:150px; width:300px\" /></span></span></span></span></p>",
      "unique_key": "Q3547339",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384502,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. &nbsp;C. Quinidine</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Quinidine and procainamide are class IA anti-arrhythmic agents. These blocks Na+ channel along with potassium channel as well. This increases action potential duration (APD), which leads to QT prolongation.</span></span></span></span></span><br />\r\n\t<br />\r\n\t&nbsp;</li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica\"><span style=\"font-family:Helvetica\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/06/pharmc-1-11.jpg\" style=\"height:201px; width:400px\" /></span></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A. Tocainide</span></strong></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Tocainide is a Class IB anti-arrhythmic drug. These drugs block Na+ channels and open K+ channels, reducing the slope of phase 4 of the action potential. This effect shortens the action potential duration.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/22/screenshot-2024-07-22-180023.png\" style=\"height:241px; width:400px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">B. Propranolol</span></strong></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Propranolol is a beta-receptor blocker and a Class II anti-arrhythmic. It works primarily by inhibiting sympathetic input to the heart, reducing heart rate, and decreasing the force of contraction. It does not directly affect the action potential duration in the same way as Class I drugs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">D. Lignocaine</span></strong></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Lignocaine (Lidocaine) is a Class IB anti-arrhythmic drug. It shortens the action potential duration by blocking Na+ channels and opening K+ channels. This effect is the opposite of what is shown in the graph.</span></span></span></p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/22/screenshot-2024-07-22-180053.png\" style=\"height:246px; width:400px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Note &ndash; </span></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Class 1c agents like Flecainide and Encainide block sodium channels with no action on potassium channel. The image below illustrates the action potential changes when a class 1c anti-arrhythmic is used.</span></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/22/screenshot-2024-07-22-180124.png\" style=\"height:240px; width:400px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Class IA anti-arrhythmic agents like Quinidine prolong the action potential duration by blocking sodium and potassium channels, making them effective in treating both atrial and ventricular arrhythmias. This effect is clearly reflected in the graph provided, distinguishing it from other classes of anti-arrhythmic drugs.</span></span></span></span></p>",
      "correct_choice_id": 28702,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5932,
      "choices": [
        {
          "id": 23698,
          "text": "<p><span style=\"font-size:12.0pt;\">Serum FSH levels</span></p>"
        },
        {
          "id": 23699,
          "text": "<p><span style=\"font-size:12.0pt;\">Serum testosterone levels</span></p>"
        },
        {
          "id": 23700,
          "text": "<p><span style=\"font-size:12.0pt;\">Testicular Biopsy</span></p>"
        },
        {
          "id": 23701,
          "text": "<p><span style=\"font-size:12.0pt;\">Serum LH level</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A couple presents to the infertility clinic with a normal hysterosalpingogram and a semen analysis report with azoospermia. Which of the following test is useful to differentiate between an obstructive and a testicular cause?&nbsp;</span>(INICET MAY 2021)</p>",
      "unique_key": "Q9527620",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384483,
      "difficulty_level": "difficult",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Testicular Biopsy</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">The absence of sperm in semen is known as azoospermia. It can be due to:</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:12.0pt;\">Pre-testicular azoospermia due to a hypothalamic or pituitary abnormality (hypogonadotropic hypogonadism)</span></li><li><span style=\"font-size:12.0pt;\">Testicular failure or non-obstructive azoospermia</span></li><li><span style=\"font-size:12.0pt;\">Post-testicular obstruction implies normal spermatogenesis but failure to deliver the sperm into the ejaculate because of ducal obstruction.</span></li></ul></li><li><span style=\"font-size:12.0pt;\">In testicular cause of azoospermia, there will be absent or very few sperms on biopsy whereas in obstructive azoospermia, there will be normal sperms on biopsy</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Serum FSH levels&nbsp;</strong>and <strong>Option B. Serum testosterone levels</strong> are important for spermatogenesis</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">FSH levels can be used to differentiate hypogonadotrophic hypogonadism from other causes of testicular failure</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Serum LH level</strong>: LH is a non-specific test in evaluation of azoospermia</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">A testicular biopsy is useful to differentiate between an obstructive and a testicular cause of Azoospermia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Ref: Page no 233, DC Dutta’s Textbook of Gynecology 6the edition</strong></span></p>",
      "correct_choice_id": 23700,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 73699,
      "choices": [
        {
          "id": 293737,
          "text": "<p><span style=\"font-size:16px;\">0.9 hours</span></p>"
        },
        {
          "id": 293738,
          "text": "<p><span style=\"font-size:16px;\">40 hours</span></p>"
        },
        {
          "id": 293739,
          "text": "<p><span style=\"font-size:16px;\">0.5 hours</span></p>"
        },
        {
          "id": 293740,
          "text": "<p><span style=\"font-size:16px;\">20 hours</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:16px;\">A young male weighing 46 kg was treated with a drug. It has a Vd of 6 L/kg and clearance of 4.6 L/hour. What is the approximate half-life of this drug?&nbsp;(INICET NOV 2024)</span></p>",
      "unique_key": "Q4727491",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384472,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. B) 40 hours</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Explanation:</strong>&nbsp;</span></p><p><br><span style=\"font-size:16px;\">The half-life can be calculated using the formula:</span></p><p><span style=\"font-size:16px;\">&nbsp;</span><br><span style=\"font-size:16px;\">t1/2 = 0.693 × Vd/Clearance</span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:16px;\">Vd given is 6 L/kg, so total Vd = 6 × 46 = 276 L</span></li><li><span style=\"font-size:16px;\">Clearance = 4.6 L/hour Therefore: t1/2 = 0.693 × 276/4.6 ≈ 0.693 × 60 ≈ 40 hours</span></li></ul><p><br><span style=\"font-size:16px;\"><strong>Educational Objective:</strong>&nbsp;</span></p><p><br><span style=\"font-size:16px;\">The formula for calculating half-life (t1/2 = 0.693 × Vd/Clearance) and remember to account for total Vd when given in L/kg by multiplying with body weight.</span></p>",
      "correct_choice_id": 293738,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9835,
      "choices": [
        {
          "id": 39307,
          "text": "<p><span style=\"font-size:12.0pt;\">Lipids without MHC proteins</span></p>"
        },
        {
          "id": 39308,
          "text": "<p><span style=\"font-size:12.0pt;\">Peptides with MHC proteins</span></p>"
        },
        {
          "id": 39309,
          "text": "<p><span style=\"font-size:12.0pt;\">CD20</span></p>"
        },
        {
          "id": 39310,
          "text": "<p><span style=\"font-size:12.0pt;\">CD3</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Gamma delta T cell receptors (γδ TCRs) recognizes? </span>(AIIMS MAY 2018)</p>",
      "unique_key": "Q2851723",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384482,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans.</strong>&nbsp;<strong>A) Lipids without MHC proteins</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">A small population of mature T cells expresses a type of TCR composed of γ and δ polypeptide chains. <strong>The γδ TCR recognizes peptides, lipids, and small molecules, without a requirement for display by MHC proteins</strong>. γδ T cells tend to aggregate at epithelial surfaces, such as the skin and mucosa of the gastrointestinal and urogenital tracts, suggesting that these cells are sentinels that protect against microbes that try to enter through epithelia</span></li><li><span style=\"font-size:12.0pt;\"><strong>The αβ TCR recognizes peptide antigens that are displayed by major histocompatibility complex (MHC. molecules on the surfaces of antigen-presenting cells (APCs).</strong> By limiting the specificity of T cells for peptides displayed by cell surface MHC molecules, <strong>called MHC restriction</strong>, the immune system ensures that T cells see only cell-associated antigens (e.g., those derived from microbes in cells).</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Peptides with MHC proteins</strong>: This is characteristic of <strong>αβ TCRs</strong>, not γδ TCRs.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. CD20</strong>: CD20 is a B cell marker, not a target recognized by T cell receptors.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. CD3</strong>: CD3 is a signaling molecule associated with the T cell receptor complex but is not a specific target recognized by the TCR itself.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Gamma delta T cell receptors (γδ TCRs)&nbsp;</strong>are unique in that they can recognize <strong>lipids and other molecules without the need for MHC protein presentation</strong>, distinguishing them from the more common αβ T cells.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Ref: Robbin and Cotran pathologic basis of disease 8th edition pg 353</strong></span></p>",
      "correct_choice_id": 39307,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5746,
      "choices": [
        {
          "id": 22956,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Single dose of 0.75 after 12 hrs</span></span></span></p>"
        },
        {
          "id": 22957,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Two doses 12 hrs apart</span></span></span></p>"
        },
        {
          "id": 22958,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Three doses 12 hrs apart</span></span></span></p>"
        },
        {
          "id": 22959,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">None of the above</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For emergency contraception, a single tab of 0.75 mg of LNG was taken, it should be followed by which of the following?&nbsp;</span></span><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(INICET NOV 2017)</span></span></span></span></p>",
      "unique_key": "Q9972601",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384495,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Single dose of 0.75 after 12 hrs</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In this case, the 2nd dose of LNG 0.75 mg (levonorgestrel) is taken after 12 hours.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">One tablet of LNG 0.75mg should be taken within 72 hours of unprotected intercourse and another 12 hours later. </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alternately, two tablets (of 0.75mg) or a single 1.5mg tablet can be taken as a single dose. </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The tablets can be offered up to 72h of an act of unprotected intercourse, but the efficacy decreases with the longer coital-drug interval.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other emergency contraceptives available: </span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-094530.png\" style=\"height:301px; width:1000px\" /></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Emergency contraception using levonorgestrel requires a follow-up dose of 0.75 mg taken 12 hours after the initial dose to ensure efficacy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 243, Berek and Novak&rsquo;s Gynecology 15<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 22956,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 60475,
      "choices": [
        {
          "id": 241193,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">4-3-2-1</span></span></p>"
        },
        {
          "id": 241194,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">4-2-3-1</span></span></p>"
        },
        {
          "id": 241195,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">4-3-1-2 </span></span></p>"
        },
        {
          "id": 241196,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">4-1-2-3</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Arrange the following steps of dilation and curettage in sequence. (INICET NOV 2022)&nbsp;</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serial dilation</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Curettage</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Uterine sound</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Assessment of uterine size and direction</span></span></span></li>\r\n</ol>",
      "unique_key": "Q3041515",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384513,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) 4-3-1-2 </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The correct sequence of dilation and curettage (D&amp;C) is <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">4-3-1-2</span></strong>:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Assessment of uterine size and direction:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This ensures that the uterine position is understood before further intervention.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Uterine sound:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is used to determine the length and angle of the uterine cavity.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serial dilation:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Gradual dilation of the cervical canal is done using graduated dilators to prepare for the curettage procedure.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Curettage:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> A curette is used to scrape the endometrial lining or remove tissue from the uterine cavity.</span></span></span></li>\r\n</ol>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The steps of the procedure ensure the safe and proper removal of uterine contents, while minimizing trauma to the cervix and uterine wall.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The correct sequence for performing a dilation and curettage is <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">4-3-1-2</span></strong>, starting with assessing the uterine size and direction, followed by uterine sounding, dilation, and finally curettage. This order is crucial to ensure safe and effective treatment.</span></span></span></p>",
      "correct_choice_id": 241195,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 24696,
      "choices": [
        {
          "id": 98745,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2, 3 and 4</span></p>"
        },
        {
          "id": 98746,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2 and 3</span></p>"
        },
        {
          "id": 98747,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2</span></p>"
        },
        {
          "id": 98748,
          "text": "<p><span style=\"font-size:12.0pt;\">3, 4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient complains of persistent, dull, aching pain in both legs. He reports a history of extended periods of standing and mentions having visibly twisted veins in his legs. What tests would typically be conducted to assess saphenofemoral incompetence in this scenario? </span><span style=\"font-size:11pt;\">(</span><span style=\"font-size:12.0pt;\">INICET MAY 2023)</span></p><p>&nbsp;</p><ol><li><span style=\"font-size:12.0pt;\">Brodie Trendelenburg Test</span></li><li><span style=\"font-size:12.0pt;\">Morrissey's test</span></li><li><span style=\"font-size:12.0pt;\">Fegan's test</span></li><li><span style=\"font-size:12.0pt;\">Modified Perthes test</span></li></ol>",
      "unique_key": "Q6596810",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384473,
      "difficulty_level": "intermediate",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) 1, 2</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The Brodie Trendelenburg and Morrissey's tests aim to assess the competency of the saphenofemoral valve, while the Fegan's method is utilized to identify perforator incompetence. Meanwhile, the Modified Perthe's test serves as a diagnostic measure for deep vein thrombosis (DVT).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>1. Brodie–Trendelenburg Test:</strong></span><span style=\"font-size:11pt;\">&nbsp;</span><span style=\"font-size:12.0pt;\"> The affected leg is raised so that the veins are emptied by gravity. Around the upper thigh region, a tourniquet is applied, sufficiently tightly to constrict the saphenous vein. The femoral vein blood flow isn’t obstructed. The patient is then asked to stand and the degree of filling of the saphenous vein is noted. On release of tourniquet, rapid filling of great saphenous vein is noted from above downwards in case of saphenofemoral junction incompetence.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>2. Morrissey’s cough impulse test</strong></span><span style=\"font-size:14.6667px;\"><strong>:</strong></span><span style=\"font-size:12pt;\">&nbsp;Limb is elevated to empty the veins and then patient is asked to cough. An expansile impulse is felt on palpation at saphenofemoral junction.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>3. Fegan's test</strong></span><span style=\"font-size:14.6667px;\"><strong>:</strong></span><span style=\"font-size:12pt;\">&nbsp;This is method is used to identify perforator incompetence. Site where perforators pierce deep fascia bulges on standing and depresses on lying supine, which can be felt as defects in deep fascia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>4. Modified Perthes test:</strong>&nbsp;This test is done to rule out Deep vein thrombosis. First veins are emptied and a tourniquet is placed around the thigh and then instructed to stand up. Then patient is asked to rapidly stand up and down on their toes and walk quickly for a few minutes. If filling of veins is observed, then this indicates Deep vein thrombosis. This is a painful test and is rarely used.</span></p>",
      "correct_choice_id": 98747,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10122,
      "choices": [
        {
          "id": 40454,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acid Citrate dextrose</span></span></span></p>"
        },
        {
          "id": 40455,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Citrate phosphate dextrose</span></span></span></p>"
        },
        {
          "id": 40456,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Citrate phosphate 2 dextrose</span></span></span></p>"
        },
        {
          "id": 40457,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Citrate phosphate dextrose adenine &ndash; 1</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:left\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following can be used to store blood for up to 35 days? </span></span></span>(AIIMS MAY 2017)</p>",
      "unique_key": "Q8451894",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384457,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) Citrate phosphate dextrose adenine &ndash; 1 </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Citrate-phosphate-dextrose solution with adenine (CPDA) is an anticoagulant and preservative for storage of blood. It can prolong red blood cell storage life up to 35 days. It <strong>maintains platelet viability</strong>. Usage of <strong>CPDA improves post-transfusion visibility and improves glucose and ATP levels in blood. CPDA can increase serum uric acid levels (due to adenine component).</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The shelf life of storage of other options:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Acid Citrate dextrose - 21 days</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Citrate-phosphate dextrose - 21 days</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Citrate Phosphate 2 Dextrose (CP2D):</span></strong><span style=\"font-size:12.0pt\"> 21 days</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Citrate Phosphate Dextrose Adenine (CPDA-1) can be used to store blood for up to 35 days, making it the solution with the longest preservation capability among the options provided.</span></span></span></p>",
      "correct_choice_id": 40457,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 49025,
      "choices": [
        {
          "id": 195675,
          "text": "<p><span style=\"font-size:18px;\">Doxycycline alone</span></p>"
        },
        {
          "id": 195676,
          "text": "<p><span style=\"font-size:18px;\">Doxycycline + Azithromycin</span></p>"
        },
        {
          "id": 195677,
          "text": "<p><span style=\"font-size:18px;\">Ceftriaxone + Doxycycline</span></p>"
        },
        {
          "id": 195678,
          "text": "<p><span style=\"font-size:18px;\">Ceftriaxone alone</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:18px;\"><strong>A 60-year-old farmer reports symptoms of fever, body pain, and a cough. A physical examination reveals a black lesion as depicted in the accompanying image. Laboratory tests confirm the presence of IgM antibodies indicative of Scrub Typhus infection. What treatment approach would be most advisable in this case? </strong><i><strong>[INICET NOV 2023]</strong></i></span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/13/screenshot-2024-06-13-111337.JPG\" alt=\"\" width=\"300\" height=\"175\"></span></p><p>&nbsp;</p>",
      "unique_key": "Q2623036",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384518,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:18px;\"><strong>Ans. (a) Doxycycline alone</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:18px;\">This black lesion is Eschar and this is the acute case of Scrub Typhus.</span></li><li><span style=\"font-size:18px;\">Causative organism - Rickettsia tsutsugamushi; Vector - Mite</span></li><li><span style=\"font-size:18px;\">The preferred approach depends on the severity of the condition and individual patient considerations.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>Option A. Doxycycline Alone</strong>:</span></p><p>&nbsp;</p><ol><li><span style=\"font-size:18px;\"><strong>Use</strong>: This is the first-line treatment for Scrub Typhus.</span></li><li><span style=\"font-size:18px;\"><strong>Mechanism</strong>: Doxycycline works by inhibiting protein synthesis in bacteria, effectively controlling the infection.</span></li><li><span style=\"font-size:18px;\"><strong>Why Prefer</strong>: It's highly effective and typically well-tolerated, making it suitable for most cases unless contraindicated.</span></li></ol><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>Option B. Doxycycline + Azithromycin</strong>: Used when there is co-infection with other pathogens that azithromycin can cover or when doxycycline alone isn't adequately effective.</span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>Option C. Ceftriaxone + Doxycycline</strong>: This combination might be used in more severe cases or when the patient has complications that might benefit from a broader antibiotic coverage.</span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>Option D. Ceftriaxone Alone</strong>: While effective against many types of bacteria, it's not the targeted treatment for Scrub Typhus and generally not recommended unless other options are contraindicated.</span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>Educational Objective </strong>:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:18px;\">Doxycycline alone is usually sufficient and most advisable for uncomplicated Scrub Typhus.&nbsp;</span></li><li><span style=\"font-size:18px;\">Combination therapies may be considered in specific clinical scenarios where co-infections or severe presentations are evident.</span></li></ul>",
      "correct_choice_id": 195675,
      "solution_audio": null,
      "solution_video": "https://media.cerebellumacademy.com/media/public/question_media/solution/video/49025/INI-CET_Nove_2023_PSM_Q_-_5.mp4",
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "top",
      "tags": [
        "ClinicalVignette",
        "ImageBased",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": "https://media.cerebellumacademy.com/media/public/question_media/solution/video/49025/INI-CET_Nove_2023_PSM_Q_-_5.mp4",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 514,
      "choices": [
        {
          "id": 2052,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"color:black\">1 min</span></span></span></span></p>"
        },
        {
          "id": 2053,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"color:black\">3 min</span></span></span></span></p>"
        },
        {
          "id": 2054,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"color:black\">5-7 min</span></span></span></span></p>"
        },
        {
          "id": 2055,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"color:black\">5 min</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The time required for preoxygenation before tracheal intubation is?(AIIMS NOV 2017)</span></span></p>",
      "unique_key": "Q9713819",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384480,
      "difficulty_level": "beginner",
      "subjects_id": [
        19
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. 3 min</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Preoxygenation or denitrogenation is the process of replacing nitrogen in the lungs with oxygen. This is typically done by giving 100% oxygen to the patient for 3 minutes through a tight-fitting mask or by asking them to take 8 vital capacity breaths. This process helps to lengthen the apnea time, providing an improved margin of safety while the anesthesiologist secures the airway and resumes ventilation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">There are two main methods commonly used for preoxygenation:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The first method involves utilizing tidal volume ventilation through a face mask for a duration of 3 minutes. This technique allows for the exchange of approximately 95% of the gas present in the lungs.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The second method relies on vital capacity breaths to achieve effective preoxygenation in a shorter time frame. While four breaths over 30 seconds are not as efficient as the tidal volume method, it may still be deemed acceptable in specific clinical scenarios. Research has indicated that eight breaths over a span of 60 seconds are more effective for preoxygenation.</span></span></span></li>\r\n</ol>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. 1 min:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This duration is insufficient for effective preoxygenation, as it does not allow adequate time to replace the nitrogen in the lungs with oxygen.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. 5-7 min:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While longer preoxygenation can ensure thorough denitrogenation, it is not typically necessary beyond the 3 minutes required for effective preoxygenation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. 5 min</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Preoxygenation for this duration can be effective, but the standard practice is to use 3 minutes as it is usually sufficient to achieve the desired effect.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective :</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Preoxygenation for tracheal intubation is effectively achieved by administering 100% oxygen for 3 minutes through a tight-fitting mask or by taking 8 vital capacity breaths.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Ref: Miller&rsquo;s Anesthesia, 9<sup>th</sup> Ed. Pg</span></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>1380</strong></span></span></span></p>",
      "correct_choice_id": 2053,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "CriteriaBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 63307,
      "choices": [
        {
          "id": 252445,
          "text": "<p><span style=\"font-size:12.0pt;\">Call a vascular surgeon</span></p>"
        },
        {
          "id": 252446,
          "text": "<p><span style=\"font-size:12.0pt;\">Place generalized sutures in the area of bleeding</span></p>"
        },
        {
          "id": 252447,
          "text": "<p><span style=\"font-size:12.0pt;\">Elevate the endopelvic fascia by inserting fingers in the vagina</span></p>"
        },
        {
          "id": 252448,
          "text": "<p><span style=\"font-size:12.0pt;\">Insert a surgical drain to monitor further bleeding</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11.0pt;\">A 45-year-old female undergoes a Burch colposuspension for stress urinary incontinence. During the procedure, there is significant bleeding in the space of Retzius, and the source of bleeding cannot be clearly visualized. What is the most appropriate next step in the management?</span></p>",
      "unique_key": "Q1642625",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384505,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Elevate the endopelvic fascia by inserting fingers in the vagina</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Elevating the <strong>endopelvic fascia by inserting fingers in the vagina</strong> helps to identify the bleeding vessels by putting tension on the tissues, making it easier to visualize and grasp the bleeders, thus controlling the hemorrhage during Burch colposuspension.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options</strong>:</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Call a vascular surgeon</strong>: In most cases of intraoperative bleeding in the space of Retzius, initial management is performed by the surgical team rather than calling a vascular surgeon unless the bleeding is extensive and cannot be controlled by routine methods.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Place generalized sutures in the area of bleeding</strong>: Applying generalized sutures without clear visualization may inadvertently damage other important structures, such as vessels or nerves, and does not guarantee control of the actual bleeding site.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Insert a surgical drain to monitor further bleeding</strong>: While inserting a surgical drain is useful for postoperative monitoring, it is not a solution for active bleeding during surgery. The first goal is to achieve hemostasis before the placement of a drain.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective</strong>:</span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:12.0pt;\">During pelvic surgeries, if significant bleeding occurs in the <strong>space of Retzius</strong> and visualization is difficult, <strong>lifting the endopelvic fascia by placing fingers in the vagina</strong> can facilitate hemostasis.</span></li><li><span style=\"font-size:12.0pt;\">The <strong>Burch colposuspension</strong> procedure aims to correct stress urinary incontinence by suspending the bladder neck.</span></li><li><span style=\"font-size:12.0pt;\">Proper intraoperative management of bleeding can prevent complications, and it is essential to stabilize the patient before additional interventions.</span></li></ul>",
      "correct_choice_id": 252447,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9878,
      "choices": [
        {
          "id": 39478,
          "text": "<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">GATA1</span></span></span></p>"
        },
        {
          "id": 39479,
          "text": "<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">PIT1</span></span></span></p>"
        },
        {
          "id": 39480,
          "text": "<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">ТРІТ</span></span></span></p>"
        },
        {
          "id": 39481,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">SF1</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">A patient presented to the OPD with long hands and feet, and a protruding lower jaw. Which of the following genes is most likely implicated in this scenario? </span></span></span>(INICET NOV 2020)</p>",
      "unique_key": "Q3157840",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384485,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) PIT1</span></strong> </span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Mutations of the pituitary-specific gene <strong>PIT-1</strong> can lead to the development of a somatotroph adenoma which produces elevated levels of GH Growth hormone (and IGF-1) which can lead to <strong>acromegaly </strong>as given in the clinical scenario above.</span></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Somatotrophs, mammosomatotrophs, and lactotrophs are derived from stem cells that express the pituitary transcription factor, PIT-1.</span></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">If the increased levels of GH are present after closure of the epiphyses, acromegaly develops. In this condition, growth is most conspicuously seen in</span></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Skin and soft tissues, viscera (thyroid, heart, liver, and adrenals).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">The bones of the face, hands, and feet are thickened and enlarged.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Bone density may increase (hyperostosis) in both the spine and the hips.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Enlargement and protrusion of the jaw is seen (prognathism), and broadening of the lower face.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">The feet and hands are enlarged, and the fingers become thickened and sausage-like.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/09/04/screenshot-2024-09-04-181302.png\" style=\"height:561px; width:500px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">GH excess can also be associated with a variety of other manifestations, like gonadal dysfunction, <strong>diabetes mellitus</strong>, generalized <strong>muscle weakness, hypertension, arthritis, congestive heart failure</strong>, and an increased risk of <strong>gastrointestinal cancers</strong>.</span></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A. GATA1:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> This gene is associated with hematopoiesis and mutations in GATA1 are linked to blood disorders, not acromegaly.</span></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C. TPIT (TBX19):</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> This gene is involved in the development of corticotroph cells in the pituitary and is associated with ACTH production, not GH.</span></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D. SF1 (Steroidogenic factor 1):</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> SF1 is important in the development of the adrenal glands and gonads, and its mutations are associated with disorders of sex development, not acromegaly.</span></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">PIT1&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">mutations are implicated in the development of somatotroph adenomas, leading to <strong>acromegaly</strong> with features such as enlarged hands, feet, and a protruding lower jaw.</span></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref:&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Robbin and Cotran pathological basis of disease 8<sup>th</sup> edition pg 2129</span></strong></span></span></p>",
      "correct_choice_id": 39479,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4066,
      "choices": [
        {
          "id": 16243,
          "text": "<p><span style=\"font-size:12.0pt;\">Presynaptic inhibition of GABA and glycine release</span></p>"
        },
        {
          "id": 16244,
          "text": "<p><span style=\"font-size:12.0pt;\">Presynaptic inhibition of Ach receptors</span></p>"
        },
        {
          "id": 16245,
          "text": "<p><span style=\"font-size:12.0pt;\">Postsynaptic inhibition of GABA</span></p>"
        },
        {
          "id": 16246,
          "text": "<p><span style=\"font-size:12.0pt;\">Cleavage of SNARE proteins, preventing Ach release</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45-year-old man developed generalized muscle spasm with arching of his back as shown in the image, a few days after sustaining a puncture wound to his leg. The toxin responsible for this type of abnormal posturing acts by which of the following mechanisms? (INICET MAY 2021)</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/03/31/1-micro-48.jpg\" alt=\"\" width=\"300\" height=\"112\"></span></p>",
      "unique_key": "Q8640707",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384479,
      "difficulty_level": "beginner",
      "subjects_id": [
        6
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Presynaptic inhibition of GABA and glycine release</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">This abnormal posturing is caused by tetanospasmin which is produced by <strong>clostridium tetani</strong>. It <strong>inhibits presynaptic GABA and glycine release.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/03/31/1-micro-49.jpg\" alt=\"\" width=\"400\" height=\"205\"></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Clostridium tetani is an <strong>obligate anaerobic, gram-positive bacillus with terminal round spore (drumstick appearance).</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Tetanus is manifested by skeletal muscle spasms and autonomic nervous system disturbance. <strong>Tetanus only affects skeletal muscle, smooth muscle, and cardiac muscle function normally.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">C. tetani produces two exotoxins–tetanolysin and tetanospasmin.</span></p><p>&nbsp;</p><ol><li><span style=\"font-size:12.0pt;\">Tetanolysin is a heat-labile, oxygen-labile hemolysin antigenically related to the oxygen-labile hemolysins produced by C. perfringens, S. pyogenes, and S. pneumoniae. Tetanolysin damages otherwise viable tissue surrounding the infection and optimizes the conditions for bacterial multiplication.</span></li><li><span style=\"font-size:12.0pt;\">Tetanospasmin (or tetanus toxin) is a heat-labile, oxygen-stable, plasmid-coded neurotoxin responsible for disease manifestations. Tetanus neurotoxin is released upon cell lysis after bacterial growth under anaerobic conditions (e.g., in deep puncture wounds). It is antigenic and is specifically neutralized by its antitoxin. Its toxoid form is used for vaccine preparation.</span></li></ol><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Mechanism of Tetanus Toxin-</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Tetanus toxin binds to polysialogangliosides receptors present on motor nerve terminals which results in toxin internalization.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Following internalization, tetanus toxin gets transported in a retrograde way from the peripheral nervous system to the central nervous system by retrograde axonal transport. When tetanus toxin reaches inhibitory neuron terminals, it prevents the presynaptic release of inhibitory neurotransmitters glycine and gamma-aminobutyric acid (GABA).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Incubation period of tetanus is about 6-10 days.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/03/31/1-micro-50.jpg\" alt=\"\" width=\"400\" height=\"219\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Clinical features -</strong> Patients have prolonged muscle spasms of both flexor and extensor muscles. Patients with tetanus have spastic muscle contractions, difficulty opening the jaw (called lockjaw, <strong>“trismus</strong>”), a characteristic smile called “<strong>risus sardonicus</strong>” and contractions of back muscles resulting in backward arching (<strong>Opisthotonos </strong>position). Patients are extremely irritable, and tetanic seizures develop, brought about by violent, painful muscle contractions following some minor stimulus, such as noise.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Presynaptic inhibition of Ach receptors</strong>: This mechanism is not involved in the action of tetanospasmin. It is more relevant to the action of botulinum toxin.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Postsynaptic inhibition of GABA</strong>: This is not the mechanism of action for tetanospasmin. Tetanospasmin acts presynaptically.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Cleavage of SNARE proteins, preventing Ach release</strong>: This describes the mechanism of action of botulinum toxin, not tetanospasmin. Botulinum toxin cleaves SNARE proteins, which prevents the release of acetylcholine (Ach) at the neuromuscular junction, leading to flaccid paralysis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Tetanospasmin, the toxin responsible for tetanus, acts by inhibiting the presynaptic release of the inhibitory neurotransmitters GABA and glycine, leading to unopposed muscle contraction and the characteristic symptoms of tetanus, such as muscle spasms and opisthotonos.</span></p>",
      "correct_choice_id": 16243,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 74695,
      "choices": [
        {
          "id": 297693,
          "text": "<p><span style=\"font-size:16px;\">Dimeric Inhibin B</span></p>"
        },
        {
          "id": 297694,
          "text": "<p><span style=\"font-size:16px;\">Beta hCG</span></p>"
        },
        {
          "id": 297695,
          "text": "<p><span style=\"font-size:16px;\">AFP</span></p>"
        },
        {
          "id": 297696,
          "text": "<p><span style=\"font-size:16px;\">Unconjugated Estriol&nbsp;</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:16px;\">A 16 weeks pregnant woman planned for Anomaly scan. Following the scan, the patient was advised to take a Quadruple test. Which is not part of the Quadruple test? (INICET NOV 2024)</span></p>",
      "unique_key": "Q6093402",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384501,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. A) Dimeric Inhibin B</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">The quadruple test is a second-trimester screening test performed between 15-20 weeks of pregnancy. The correct components of the quadruple test are:</span></p><p>&nbsp;</p><ol><li><span style=\"font-size:16px;\"><strong>Alpha-fetoprotein (AFP)</strong></span></li><li><span style=\"font-size:16px;\"><strong>Beta hCG</strong></span></li><li><span style=\"font-size:16px;\"><strong>Inhibin A (not B)</strong></span></li><li><span style=\"font-size:16px;\"><strong>Unconjugated estriol</strong></span></li></ol><p>&nbsp;</p><p><span style=\"font-size:16px;\">In pregnancies with Down syndrome:</span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:16px;\">Beta hCG and Inhibin A levels are elevated</span></li><li><span style=\"font-size:16px;\">AFP and unconjugated estriol levels are decreased</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Educational Objective</strong>:&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">The quadruple test consists of four specific markers: <strong>AFP, beta hCG, Inhibin A (not B), and unconjugated estriol.</strong> Dimeric Inhibin B is not a component of this test.</span></p>",
      "correct_choice_id": 297693,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10099,
      "choices": [
        {
          "id": 40362,
          "text": "<p><span style=\"font-size:12.0pt;\">Actinomycin D</span></p>"
        },
        {
          "id": 40363,
          "text": "<p><span style=\"font-size:12.0pt;\">Bleomycin</span></p>"
        },
        {
          "id": 40364,
          "text": "<p><span style=\"font-size:12.0pt;\">Mitomycin C</span></p>"
        },
        {
          "id": 40365,
          "text": "<p><span style=\"font-size:12.0pt;\">Doxorubicin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The given condition is caused by which drug? (</span>INICET Nov 2020)</p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/19/untitled-13550.jpg\" alt=\"\" width=\"300\" height=\"360\"></p>",
      "unique_key": "Q7301973",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384511,
      "difficulty_level": "beginner",
      "subjects_id": [
        18
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Bleomycin</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">The given image shows <strong>flagellate dermatitis</strong>. It is caused by <strong>bleomycin</strong>.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Flagellate dermatoses</strong> are infrequent types of <strong>figurate dermatoses</strong> characterized by <strong>parallel lines or curves resembling whiplash marks</strong>.</span></li><li><span style=\"font-size:12.0pt;\">Bleomycin, a polypeptide <strong>chemotherapeutic</strong> agent, primarily affects the <strong>respiratory and cutaneous</strong> systems, likely due to the absence of the inactivating enzyme <strong>hydrolase</strong> in these tissues.</span></li></ul><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/27/picture5_OFqjQ6s.jpg\" alt=\"\" width=\"700\" height=\"347\"></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\"><strong>It manifests as widespread, itchy, flagellate, erythematous plaques on the trunk and extremities&nbsp;</strong>within hours to months after bleomycin administration.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Flagellate hyperpigmentation&nbsp;</strong>may persist even after the rash has resolved.</span></li><li><span style=\"font-size:12.0pt;\">While there is <strong>no specific treatment for this condition</strong>, <strong>avoiding bleomycin</strong> can lead to <strong>clearance of the symptoms</strong> over several <strong>months to years</strong>.</span></li><li><span style=\"font-size:12.0pt;\">However, re-exposure to the drug might trigger a <strong>more severe reaction.</strong></span></li><li><span style=\"font-size:12.0pt;\">Bleomycin is also associated with development of <strong>pulmonary fibrosis.</strong></span></li><li><span style=\"font-size:12.0pt;\"><strong>Peplomycin, a bleomycin derivative with reduced pulmonary toxicity</strong>, is utilized in the treatment of prostatic carcinoma and lymphomas. Nevertheless, it has been associated with flagellate erythema through mechanisms like those of bleomycin.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/27/screenshot-2023-11-27-102206.jpg\" alt=\"\" width=\"1000\" height=\"537\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Bleomycin, on the other hand, can cause skin side effects like flagellate erythema, which appears as streaky red or hyperpigmented lines on the skin, resembling the appearance in the image provided. This particular side effect is a hallmark of Bleomycin toxicity.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">For medical students and residents, it is crucial to identify <strong>bleomycin</strong> as the <strong>chemotherapeutic agent</strong> that can cause <strong>flagellate hyperpigmentation</strong>, a dermatological side effect not commonly associated with actinomycin, mitomycin C, or doxorubicin.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Ref -&nbsp;</strong></span><span style=\"color:black;font-size:12.0pt;\"><strong>Rook's Textbook of Dermatology - 9th Edition - Volume I, Chapter 4 &amp; 120, Page no 4.12 &amp; 120.8</strong></span></p><p><span style=\"color:black;font-size:12.0pt;\"><strong>Goodman &amp; Gillman’s The pharmacological basis of therapeutics 13<sup>th</sup> edition Page no 1193</strong></span></p><p><a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3702947/\"><span style=\"font-size:12.0pt;\"><strong><u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3702947/</u></strong></span></a></p><p><a href=\"https://onlinelibrary.wiley.com/share/F7KSRDKWUJX3W2GZTEAC?target=10.1002/ski2.92\"><span style=\"font-size:12.0pt;\"><strong><u>https://onlinelibrary.wiley.com/share/F7KSRDKWUJX3W2GZTEAC?target=10.1002/ski2.92</u></strong></span></a></p>",
      "correct_choice_id": 40363,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ImageBased",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1027,
      "choices": [
        {
          "id": 4104,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Venturi mask</span></p>"
        },
        {
          "id": 4105,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Hudson mask</span></p>"
        },
        {
          "id": 4106,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Non-rebreathing mask</span></p>"
        },
        {
          "id": 4107,
          "text": "<p><span style=\"font-size:12pt;\">Nasal cannula</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">In conventional oxygen therapy, which device will deliver the highest FiO<sub>2</sub>? (</span>INICET May 2021)</p>",
      "unique_key": "Q7220267",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384520,
      "difficulty_level": "beginner",
      "subjects_id": [
        19
      ],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ans. C) Non</strong>-<strong>rebreathing mask</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>FiO2 Delivery:</strong> A non-rebreathing mask can deliver an FiO2 of up to 80% at flow rates of 10-15 L/min. This mask has a reservoir bag that fills with oxygen and a one-way valve that prevents the exhaled air from entering the reservoir bag, ensuring a higher concentration of oxygen is inhaled.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Venturi mask: </strong>The Venturi mask delivers a precise FiO2, which can range from 24% to 66%, depending on the entrainment device used. It is often used in patients who require a specific oxygen concentration.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Hudson mask: </strong>This option appears to refer to a simple face mask, which can deliver up to 60% FiO2 at 10 L/min. It is less efficient in delivering high concentrations of oxygen compared to a non-rebreathing mask.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Nasal cannula: </strong>A nasal cannula typically delivers up to 44% FiO2 at a flow rate of 6 L/min. It is comfortable and used for patients who need low to moderate oxygen supplementation but cannot deliver the high concentrations achievable with a non-rebreathing mask.</span></p><h3>&nbsp;</h3><h3><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></h3><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">The non-rebreathing mask delivers the highest FiO2 in conventional oxygen therapy, capable of providing up to 80% FiO2 at flow rates of 10-15 L/min, making it suitable for patients requiring high concentrations of oxygen.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/02/screenshot-2024-07-02-151423.jpg\" alt=\"\" width=\"1000\" height=\"616\"></span></p>",
      "correct_choice_id": 4106,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "INICET",
        "InstrumentsBased",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14036,
      "choices": [
        {
          "id": 56105,
          "text": "<p><span style=\"font-size:12.0pt;\">McBurney's tenderness</span></p>"
        },
        {
          "id": 56106,
          "text": "<p><span style=\"font-size:12.0pt;\">Rovsing's sign</span></p>"
        },
        {
          "id": 56107,
          "text": "<p><span style=\"font-size:12.0pt;\">Psoas sign</span></p>"
        },
        {
          "id": 56108,
          "text": "<p><span style=\"font-size:12.0pt;\">Ballance sign</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A young boy was brought to the casualty with a history of fever and acute right lower abdominal pain. On examination, he was febrile and his pulse rate was 106 beats/min. Tenderness was felt in right iliac fossa. The CT scan image is shown below. Which of the following signs will not be seen in this disease? (AIIMS NOV 2017)</span></p><p>&nbsp;</p><p><span style=\"color:black;font-size:12pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/05/03/untitled-180.jpg\" alt=\"\" width=\"300\" height=\"216\"></span></p>",
      "unique_key": "Q4873409",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384486,
      "difficulty_level": "beginner",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. D) Ballance sign</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The patient's history and CT findings are indicative of acute appendicitis. Ballance sign is not seen in acute appendicitis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Ballance's sign is seen in splenic trauma, where dullness is seen on right flank on percussion, which doesn’t shift on lateral position.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>McBurney's tenderness</strong>: Deep tenderness at McBurney's point, known as McBurney's sign, is a sign of acute appendicitis. McBurney's point is a point at one-third of the distance from the anterior superior iliac spine and umbilicus.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Rovsing sign</strong>: Rovsing sign is seen in appendicitis. Deep palpation of the left iliac fossa causes pain in the right iliac fossa.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Psoas sign</strong>: Psoas sign is seen in appendicitis. Sometimes, the inflamed appendix lies on the psoas muscle, and the patient, often a young adult, will lie with the right hip flexed, for pain relief.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Findings on CT that are suggestive of acute appendicitis include:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Appendiceal dilatation (&gt;6 mm in diameter)</span></li><li><span style=\"font-size:12.0pt;\">Appendiceal wall thickening (&gt;3 mm) and enhancement</span></li></ul>",
      "correct_choice_id": 56108,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54876,
      "choices": [
        {
          "id": 218965,
          "text": "<p><span style=\"font-size:12.0pt;\">Congenital nasolacrimal duct obstruction</span></p>"
        },
        {
          "id": 218966,
          "text": "<p><span style=\"font-size:12.0pt;\">Congenital entropion</span></p>"
        },
        {
          "id": 218967,
          "text": "<p><span style=\"font-size:12.0pt;\">Congenital glaucoma</span></p>"
        },
        {
          "id": 218968,
          "text": "<p><span style=\"font-size:12.0pt;\">Congenital distichiasis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 3-month-old child presents with photophobia and watering. Which of the following cannot be the cause? (INICET MAY 2024)</span></p>",
      "unique_key": "Q7221850",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384469,
      "difficulty_level": "intermediate",
      "subjects_id": [
        8
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Congenital nasolacrimal duct obstruction</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Photophobia and watering in a 3-month-old child can be caused by various conditions. Here’s a closer look at each condition:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\"><strong>Congenital nasolacrimal duct obstruction</strong>: This condition typically presents with excessive tearing (lacrimation) due to blockage of the nasolacrimal duct. However, it does not cause photophobia. Photophobia indicates sensitivity to light, which is not a feature of nasolacrimal duct obstruction.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Congenital entropion</strong>: This condition involves the inward turning of the eyelid, causing the eyelashes to rub against the cornea. This can lead to corneal abrasions, resulting in both photophobia and watering.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Congenital glaucoma</strong>: This is characterized by increased intraocular pressure, which can lead to a triad of symptoms: photophobia, lacrimation, and blepharospasm (eyelid twitching). It is a serious condition that requires prompt medical attention.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Congenital distichiasis</strong>: This condition involves an extra row of eyelashes, which can irritate the cornea, leading to corneal abrasions. This irritation can cause both photophobia and lacrimation.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Option:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Congenital nasolacrimal duct obstruction</strong>: As explained, this condition causes lacrimation but not photophobia. This makes it the to the question of which condition cannot cause photophobia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Congenital nasolacrimal duct obstruction is associated with excessive tearing but does not cause photophobia. Other conditions like congenital entropion, congenital glaucoma, and congenital distichiasis can cause both photophobia and watering due to corneal involvement and irritation.</span></p>",
      "correct_choice_id": 218965,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10294,
      "choices": [
        {
          "id": 41142,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Spironolactone</span></span></span></p>"
        },
        {
          "id": 41143,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Potassium binding resins</span></span></span></p>"
        },
        {
          "id": 41144,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydrocortisone</span></span></span></p>"
        },
        {
          "id": 41145,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Broad spectrum antibiotics</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 3-week neonate presents with ambiguous genitalia with Na+ - 127, K+ - 6 meq with a BP of 50/22 mm Hg. Along with IV fluids, what specific management is done? (AIIMS MAY 2019)</span></span></p>",
      "unique_key": "Q3903658",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384503,
      "difficulty_level": "beginner",
      "subjects_id": [
        13
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Hydrocortisone</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The neonate in this case presents with ambiguous genitalia, hyponatremia (Na+ 127 mEq/L), hyperkalemia (K+ 6 mEq/L), and hypotension (BP 50/22 mm Hg). These findings are suggestive of congenital adrenal hyperplasia (CAH), most likely due to 21-hydroxylase deficiency. CAH is an autosomal recessive disorder characterized by a deficiency in cortisol production, leading to an overproduction of androgens and a deficiency in aldosterone, which causes salt-wasting and hyperkalemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The treatment of choice in this situation is hydrocortisone, which replaces the deficient glucocorticoids. Hydrocortisone will help manage the adrenal insufficiency by increasing cortisol levels, thereby normalizing blood pressure, glucose levels, and reducing the overproduction of androgens. In addition to hydrocortisone, mineralocorticoid replacement with fludrocortisone may also be required to address the salt-wasting.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<h3><span style=\"font-size:13.5pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></h3>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Spironolactone</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is a potassium-sparing diuretic and aldosterone antagonist. It is not appropriate in this scenario as it would exacerbate hyperkalemia and does not address the underlying cortisol deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Potassium binding resins</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: These are used to treat hyperkalemia by promoting the excretion of potassium in the stool. While they may reduce potassium levels, they do not address the underlying cause of the hyperkalemia, which is the deficiency in cortisol and aldosterone.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Broad spectrum antibiotics</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:&nbsp;</span></span></span><span style=\"font-family:Calibri,sans-serif; font-size:12pt\">Antibiotics are used to treat infections and are not relevant in managing CAH unless the patient has a concurrent infection.</span></p>\r\n\r\n<h3>&nbsp;</h3>\r\n\r\n<h3><span style=\"font-size:13.5pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></h3>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydrocortisone is the first-line treatment for congenital adrenal hyperplasia (CAH) with 21-hydroxylase deficiency, which presents with ambiguous genitalia, hyponatremia, hyperkalemia, and hypotension in neonates.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/17/screenshot-2023-11-17-114802.png\" style=\"height:790px; width:805px\" /></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/17/02.jpg\" style=\"height:501px; width:700px\" /></span></strong></span></span></p>",
      "correct_choice_id": 41144,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11864,
      "choices": [
        {
          "id": 47422,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Antihistone antibodies</span></span></p>"
        },
        {
          "id": 47423,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anti-dsDNA antibodies</span></span></p>"
        },
        {
          "id": 47424,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anticentromere antibodies</span></span></p>"
        },
        {
          "id": 47425,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Antinuclear antibodies</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A young patient presents to the clinic with erythematous lesions over the exposed areas of the skin like hands, arms, chest, etc. She also complains of arthralgia and breathlessness. Which among the following antibodies will be useful in diagnosing this condition? (INICET NOV 2022)</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/09/13/whatsapp-image-2024-09-13-at-103830-am.jpeg\" style=\"height:257px; width:300px\" /></p>",
      "unique_key": "Q8595702",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384456,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Anti-dsDNA antibodies</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient exhibits symptoms including erythematous lesions on sun-exposed areas of the skin, arthralgia, and breathlessness, which are characteristic of Systemic Lupus Erythematosus (SLE). The rash described is typical of an SLE rash and not dermatomyositis, which presents with rashes over the knuckles known as Gottron&#39;s papules.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For diagnosing SLE, anti-dsDNA antibodies are very useful due to their high specificity. Although their sensitivity is relatively low (30-50%), the specificity is very high (&gt;90-95%), making them reliable markers for confirming the diagnosis of SLE. Anti-dsDNA antibodies are also associated with disease activity in SLE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Antihistone antibodies:</span></strong><span style=\"font-size:12.0pt\"> These are primarily associated with drug-induced lupus erythematosus, not classic SLE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Anticentromere antibodies:</span></strong><span style=\"font-size:12.0pt\"> These are typically seen in limited forms of scleroderma, particularly CREST syndrome, and are not associated with SLE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Antinuclear antibodies (ANA):</span></strong><span style=\"font-size:12.0pt\"> While ANA is a good initial screening test for SLE due to its high sensitivity, it lacks specificity. ANA can be positive in a variety of autoimmune conditions, thus it is not as specific as anti-dsDNA antibodies for diagnosing SLE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-dsDNA antibodies are highly specific for diagnosing Systemic Lupus Erythematosus (SLE), despite their moderate sensitivity.</span></span></span></p>",
      "correct_choice_id": 47423,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased",
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9971,
      "choices": [
        {
          "id": 39850,
          "text": "<p><span style=\"font-size:12.0pt;\">Acute monocytic leukemia</span></p>"
        },
        {
          "id": 39851,
          "text": "<p><span style=\"font-size:12.0pt;\">Acute myelomonocytic leukemia</span></p>"
        },
        {
          "id": 39852,
          "text": "<p><span style=\"font-size:12.0pt;\">Acute lymphoblastic leukemia</span></p>"
        },
        {
          "id": 39853,
          "text": "<p><span style=\"font-size:12.0pt;\">Juvenile myelomonocytic leukemia</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 10-year-old boy with fever, weight loss came to the hospital. On examination, he was pale and had significant lymphadenopathy. The bone marrow histology of the person is as given below. Your diagnosis is: (AIIMS NOV 2017)</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/12/51.jpg\" alt=\"\" width=\"300\" height=\"240\"></span></p>",
      "unique_key": "Q1656582",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384522,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Acute lymphoblastic leukemia</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The given scenario with bone marrow histology showing lymphoblasts (condensed nuclear chromatin, small nucleoli, scanty agranular cytoplasm) is suggestive of acute lymphoblastic leukemia.</span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/09/05/screenshot-2024-09-05-161555.png\" alt=\"\" width=\"500\" height=\"215\"></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">PBF Findings in acute lymphoblastic (ALL). The cell is large, with round to convoluted nuclei having high N/C ratio and no cytoplasmic granularity.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">ALL is more common in childhood.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Clinical features of ALL include:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Bone marrow failure - anemia, fever, infections, bleeding</span></li><li><span style=\"font-size:12.0pt;\">Mass effects due to neoplastic infiltration - bone pain, generalized lymphadenopathy, splenomegaly, hepatomegaly, and testicular enlargement</span></li><li><span style=\"font-size:12.0pt;\">CNS manifestations - headache, vomiting, and <strong>nerve palsies</strong></span></li><li><span style=\"font-size:12.0pt;\"><strong>B-ALL</strong> - Pancytopenia due to marrow involvement</span></li><li><span style=\"font-size:12.0pt;\"><strong>T-ALL</strong> - Mediastinal mass, compression of large vessels and airways in the mediastinum, lymphadenopathy, splenomegaly</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/09/05/screenshot-2024-09-05-171159.png\" alt=\"\" width=\"1000\" height=\"341\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;A. Acute monocytic leukemia</strong> and <strong>Option&nbsp;B. Acute myelomonocytic leukemia</strong>: These leukemias typically present with different morphologic features, including monoblasts and myeloblasts, which show different cytological characteristics such as cytoplasmic granularity and different nuclear morphology.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;D. Juvenile myelomonocytic leukemia (JMML)</strong>: JMML is a rare childhood leukemia with a different clinical presentation, often including hepatosplenomegaly and elevated monocyte counts, and it does not present with the lymphoblast morphology seen in ALL.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Acute lymphoblastic leukemia (ALL) in children is characterized by the presence of lymphoblasts in the bone marrow and peripheral blood, along with clinical features of bone marrow failure and organ infiltration by malignant cells.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Ref: Robbin and Cotran pathologic basis of disease, 8<sup>th</sup> edition, Page No. 1113</strong></span></p>",
      "correct_choice_id": 39852,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54843,
      "choices": [
        {
          "id": 218833,
          "text": "<p><span style=\"font-size:12.0pt;\">Hepatitis B infection</span></p>"
        },
        {
          "id": 218834,
          "text": "<p><span style=\"font-size:12.0pt;\">Caroli's disease</span></p>"
        },
        {
          "id": 218835,
          "text": "<p><span style=\"font-size:12.0pt;\">Primary sclerosing cholangitis</span></p>"
        },
        {
          "id": 218836,
          "text": "<p><span style=\"font-size:12.0pt;\">Opisthorchis V</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of these is not a risk factor for cholangiocarcinoma? (INICET MAY 2024)</span></p>",
      "unique_key": "Q8094032",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384467,
      "difficulty_level": "beginner",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Hepatitis B infection</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Cholangiocarcinoma, a type of cancer that forms in the bile ducts, has several well-established risk factors. These include chronic inflammatory conditions like primary sclerosing cholangitis (PSC), parasitic infections such as Opisthorchis viverrini, and congenital conditions like Caroli's disease. However, while Hepatitis C is recognized as a risk factor for cholangiocarcinoma, Hepatitis B is not commonly associated with this type of cancer. The confusion often arises because Hepatitis B is a major risk factor for hepatocellular carcinoma, another type of liver cancer, but not specifically for cholangiocarcinoma.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Caroli's disease</strong>: Caroli's disease is a congenital disorder characterized by the dilation of the bile ducts and is associated with an increased risk of cholangiocarcinoma.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Primary sclerosing cholangitis (PSC)</strong>: PSC is a chronic liver disease that causes inflammation and scarring of the bile ducts. It is a well-known risk factor for cholangiocarcinoma.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Opisthorchis V. (Opisthorchis viverrini)</strong>: Opisthorchis viverrini, a liver fluke, is a parasitic infection known to increase the risk of cholangiocarcinoma, especially in endemic regions.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Hepatitis B infection is not a recognized risk factor for cholangiocarcinoma. Instead, focus on chronic inflammatory conditions, parasitic infections, and certain congenital disorders as key risk factors for this type of cancer.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/26/screenshot-2024-08-26-175606.jpg\" alt=\"\" width=\"700\" height=\"305\"></span></p>",
      "correct_choice_id": 218833,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 60452,
      "choices": [
        {
          "id": 241101,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1, 2, 3</span></span></p>"
        },
        {
          "id": 241102,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">4, 3, 2, 1</span></span></p>"
        },
        {
          "id": 241103,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1, 2 </span></span></p>"
        },
        {
          "id": 241104,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">3, 4</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs is a &beta;2 agonist? </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Dopexamine</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Dipivefrine</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Fenoldopam</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Mirabegron</span></span></li>\r\n</ol>",
      "unique_key": "Q5569675",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384471,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C) 1, 2</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Dipivefrine</strong> and <strong>dopexamine</strong> are &beta;2-adrenergic receptor agonists.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Dipivefrine</strong> is a prodrug of epinephrine used to lower intraocular pressure in patients with open-angle glaucoma and ocular hypertension. It decreases aqueous humor production and enhances its outflow.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Dopexamine</strong> is a synthetic analogue of dopamine, which acts on <strong>D1</strong> and <strong>D2</strong> receptors and exhibits weak activity on <strong>&beta;2 receptors</strong>. It is used in patients with severe heart failure, sepsis, and shock.</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other Options:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Fenoldopam</strong> (Option 3) is a selective <strong>D1 receptor agonist</strong> with moderate affinity for <strong>&alpha;2-adrenergic receptors</strong>. It is primarily used as a vasodilator in hypertensive emergencies and does not act as a &beta;2 agonist.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Mirabegron</strong> (Option 4) is a <strong>&beta;3-adrenergic receptor agonist</strong> used to treat overactive bladder by relaxing the detrusor muscle, increasing bladder capacity, and improving storage symptoms. It is not a &beta;2 agonist.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Educational Objective:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Dipivefrine</strong> and <strong>dopexamine</strong> are &beta;2-adrenergic receptor agonists used in clinical settings for conditions such as glaucoma and heart failure, respectively. Recognizing drug-receptor interactions is essential for understanding their therapeutic applications.</span></span></p>",
      "correct_choice_id": 241103,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13725,
      "choices": [
        {
          "id": 54861,
          "text": "<p><span style=\"font-size:12.0pt;\">Neer classification grade 4</span></p>"
        },
        {
          "id": 54862,
          "text": "<p><span style=\"font-size:12.0pt;\">Ideberg classification grade 4</span></p>"
        },
        {
          "id": 54863,
          "text": "<p><span style=\"font-size:12.0pt;\">Garden classification grade 3</span></p>"
        },
        {
          "id": 54864,
          "text": "<p><span style=\"font-size:12.0pt;\">Schatzker classification grade 5</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What is the type of fracture shown in the X-ray of left shoulder? (</span>AIIMS Nov 2017)</p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/05/02/untitled-622.jpg\" alt=\"\" width=\"254\" height=\"301\"></p>",
      "unique_key": "Q7487754",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384468,
      "difficulty_level": "beginner",
      "subjects_id": [
        15
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A. Neer classification grade 4</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>IMPORTANT CLASSIFICATIONS OF VARIOUS FRACTURES</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/07/screenshot-2024-02-07-145054.jpg\" alt=\"\" width=\"1000\" height=\"889\"></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>NEER CLASSIFICATION OF PROXIMAL HUMERUS FRACTURE</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">The classification consists of four major groupings, based on the number of displaced parts.</span></li><li><span style=\"font-size:12.0pt;\">One-part fracture:</span><ul><li><span style=\"font-size:12.0pt;\">Fracture lines involves 1 to 4 parts</span></li><li><span style=\"font-size:12.0pt;\">No or minimal displacement (i.e. &lt;1 cm and<strong>&nbsp;</strong>&lt;45°)</span></li><li><span style=\"font-size:12.0pt;\">Account for ~70-80% of all proximal humeral fractures and are almost always treated conservatively.</span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/07/picture11.jpg\" alt=\"\" width=\"300\" height=\"319\"></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Two-part fracture:</span><ul><li><span style=\"font-size:12.0pt;\">Fracture lines involves 2 to 4 parts</span></li><li><span style=\"font-size:12.0pt;\">One part is displaced (i.e. &gt;1 cm or &gt;45°)</span></li><li><span style=\"font-size:12.0pt;\">Four possible types of two-part fractures are:&nbsp;</span><ol><li><span style=\"font-size:12.0pt;\">Surgical neck: most common</span></li><li><span style=\"font-size:12.0pt;\">Greater tuberosity</span><ul><li><span style=\"font-size:12.0pt;\">Frequently seen in anterior shoulder dislocation</span></li><li><span style=\"font-size:12.0pt;\">A lower threshold of displacement (&gt;5 mm)</span></li></ul></li><li><span style=\"font-size:12.0pt;\">Anatomical neck</span></li><li><span style=\"font-size:12.0pt;\">Lesser tuberosity: uncommon</span></li></ol></li><li><span style=\"font-size:12.0pt;\">These fractures account for approximately 20% of proximal humeral fractures.</span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/07/picture12.jpg\" alt=\"\" width=\"300\" height=\"259\"></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Three-part fracture:</span><ul><li><span style=\"font-size:12.0pt;\">Fracture lines involves 3 or 4 parts</span></li><li><span style=\"font-size:12.0pt;\">Two parts are displaced (i.e. &gt;1 cm<strong>&nbsp;</strong>or &gt;45°)</span></li><li><span style=\"font-size:12.0pt;\">2 three-part fracture patterns are encountered:</span><ol><li><span style=\"font-size:12.0pt;\">Greater tuberosity and shaft are displaced with respect to the lesser tuberosity and articular surface which remain together – most common pattern</span></li><li><span style=\"font-size:12.0pt;\">Lesser tuberosity and shaft are displaced with respect to the greater tuberosity and articular surface which remain together</span></li></ol></li><li><span style=\"font-size:12.0pt;\">These fractures account for approximately 5% of proximal humeral fractures.</span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/07/picture13.jpg\" alt=\"\" width=\"300\" height=\"289\"></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Four-part fracture:</span><ul><li><span style=\"font-size:12.0pt;\">Fracture lines involves all 4 parts</span></li><li><span style=\"font-size:12.0pt;\">Three parts are displaced (i.e.&nbsp;&gt;1 cm or &gt;45°) with respect to the 4<sup>th</sup>.</span></li><li><span style=\"font-size:12.0pt;\">These fractures are uncommon (&lt;1% of proximal humeral fractures).</span></li><li><span style=\"font-size:12.0pt;\">This pattern has poor non-operative results as the articular surface is no longer attached to any parts of the humerus. This pattern has a high incidence of&nbsp;osteonecrosis. These fractures require operative management.</span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/07/picture14.jpg\" alt=\"\" width=\"300\" height=\"288\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Ideberg classification grade 4.&nbsp;</strong>This system is used to classify the scapular fractures.</span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/07/picture15.jpg\" alt=\"\" width=\"600\" height=\"519\"></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/07/picture16.jpg\" alt=\"\" width=\"500\" height=\"219\"></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Garden classification grade 3</strong>. The&nbsp;<strong>Garden classification</strong>&nbsp;of&nbsp;subcapital femoral neck fractures&nbsp;is the most widely used. It predicts the development of&nbsp;osteonecrosis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/07/screenshot-2024-02-07-152246.jpg\" alt=\"\" width=\"1000\" height=\"424\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/07/picture17.jpg\" alt=\"\" width=\"500\" height=\"492\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Schatzker classification grade 5.</strong> This is used to classify tibial plateau fracture.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/07/picture18.jpg\" alt=\"\" width=\"1000\" height=\"513\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">The given image shows the grade 4 of the Neer’s classification of the proximal humerus fracture where all the fractured parts of the humerus are displaced.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/07/picture19.jpg\" alt=\"\" width=\"1000\" height=\"749\"></span></p>",
      "correct_choice_id": 54861,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "CriteriaBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 61162,
      "choices": [
        {
          "id": 243929,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mania</span></span></p>"
        },
        {
          "id": 243930,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Depression</span></span></p>"
        },
        {
          "id": 243931,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Schizophrenia</span></span></p>"
        },
        {
          "id": 243932,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Conversion disorder</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">La belle indifference is seen in:&nbsp; </span></span></p>",
      "unique_key": "Q6068292",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384510,
      "difficulty_level": "beginner",
      "subjects_id": [
        16
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Conversion disorder</span></span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">La belle indifference is seen in <strong>conversion disorder</strong>. This term refers to a lack of concern towards symptoms, despite the apparent severity of the disability. Although it is not pathognomonic of conversion disorder, it is often associated with it.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Conversion disorder, also known as functional neurological symptom disorder, involves the temporary loss of motor or sensory function without any underlying neurological disease. These symptoms often emerge due to internal psychological conflicts and can include paresis, non-epileptic seizures, blindness, or anesthesia of the extremities. La belle indifference highlights the emotional detachment the patient may have towards their symptoms. The onset of such symptoms is typically precipitated by psychological stress or conflict, suggesting a psychosomatic nature of the disorder.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Mania</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Mania is associated with a heightened mood, increased energy, and sometimes delusions or hallucinations, but not typically with la belle indifference.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Depression</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Depression involves low mood, anhedonia, and possible suicidal ideation, but not the apparent emotional detachment characteristic of la belle indifference.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Schizophrenia</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Schizophrenia is associated with delusions, hallucinations, and cognitive disturbances, but does not exhibit la belle indifference.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>La belle indifference</strong>, characterized by a lack of concern toward symptoms, is often associated with <strong>conversion disorder</strong> or functional neurological symptom disorder.</span></span></span></span></p>",
      "correct_choice_id": 243932,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7151,
      "choices": [
        {
          "id": 28572,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phase 1</span></span></span></p>"
        },
        {
          "id": 28573,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phase 3</span></span></span></p>"
        },
        {
          "id": 28574,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phase 2</span></span></span></p>"
        },
        {
          "id": 28575,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phase 4</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A hospital is investigating the effectiveness of statins in a multiple-centric clinical trial. The study involves 4000-5000 patients and half of them have received the drug while the other half was given a placebo. Both the subjects and the investigators are unaware of which group is getting the drug and which group is being administered the placebo. Which of the following phases of clinical trial corresponds to this scenario? (INICET NOV 2022)</span></span></p>",
      "unique_key": "Q9781682",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384517,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Phase 3 </span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;</span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">As the study is being conducted in multiple centers in a double blinded manner, where neither the physician nor the patients know what they are receiving, therefore this trial is in Phase 3.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The phases of clinical trials are as follows: -</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/22/screenshot-2024-07-22-103816.png\" style=\"height:426px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phase Zero trials are called micro-dosing studies. It is an optional trial done by some companies on small number of healthy volunteers to know the pharmacokinetics of the drug. Dose used is one-hundredth of the final human dose or 100 microgram (whichever is lower).</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pre-clinical trials are animal studies. The drugs are first tested on the small animals like rats, guinea pig etc. to know the complete pharmacokinetics.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The described clinical trial, with its large sample size, multiple centers, double-blind design, and focus on confirming the efficacy of statins, corresponds to a <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phase 3</span></strong> clinical trial. This phase is crucial for determining whether the drug is effective and safe for widespread use.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>",
      "correct_choice_id": 28573,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6088,
      "choices": [
        {
          "id": 24321,
          "text": "<p><span style=\"font-size:12pt;\">Platinum resistant if recurrence &gt; 12 months</span></p>"
        },
        {
          "id": 24322,
          "text": "<p><span style=\"font-size:12pt;\">Partial platinum resistant if recurrence is within 6-12 months</span></p>"
        },
        {
          "id": 24323,
          "text": "<p><span style=\"font-size:12pt;\">Platinum sensitive if recurrence &gt; 6 months of starting primary therapy</span></p><p>&nbsp;</p>"
        },
        {
          "id": 24324,
          "text": "<p><span style=\"font-size:12pt;\">All of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following statements is true regarding the treatment of recurrent ovarian cancer?&nbsp;</span>(INICET NOV 2022)</p>",
      "unique_key": "Q7236054",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384524,
      "difficulty_level": "difficult",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C) Platinum sensitive if recurrence &gt; 6 months &nbsp;of starting primary therapy</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Platinum-refractory disease</strong>: This includes women who progress during primary chemotherapy. It has the worst prognosis, as these patients do not respond to platinum-based chemotherapy at all.</span></li><li><span style=\"font-size:12pt;\"><strong>Platinum-resistant disease</strong>: This includes women who relapse within 6 months of completing primary therapy. Bevacizumab has been approved for the treatment of platinum-resistant disease due to its ability to inhibit angiogenesis, which is crucial for tumor growth and metastasis.</span></li><li><span style=\"font-size:12pt;\"><strong>Platinum-sensitive disease</strong>: This includes women who relapse more than 6 months after completing primary therapy. These patients are considered to have a better prognosis and are treated with a platinum-based combination such as carboplatin and paclitaxel or gemcitabine.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Platinum resistant if recurrence &gt; 12 months</strong>: This statement is incorrect. If the recurrence occurs more than 12 months after treatment, it is considered platinum-sensitive, not resistant.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Partial platinum resistant if recurrence is within 6-12 months</strong>: This statement is not a recognized classification. The classification focuses on the 6-month mark to distinguish between resistant and sensitive.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Platinum-sensitive recurrent ovarian cancer is characterized by a recurrence occurring more than 6 months after completing primary therapy.</span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/10/02/al-35.jpg\" alt=\"\" width=\"500\" height=\"275\"></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: Berek and Novak’s gynecology 15<sup>th</sup> edition pg 1387</strong></span></p>",
      "correct_choice_id": 24323,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 63631,
      "choices": [
        {
          "id": 253729,
          "text": "<p><span style=\"font-size:12.0pt;\">Statements 1 and 2 are correct</span></p>"
        },
        {
          "id": 253730,
          "text": "<p><span style=\"font-size:12.0pt;\">Statements 1, 2, and 3 are correct</span></p>"
        },
        {
          "id": 253731,
          "text": "<p><span style=\"font-size:12.0pt;\">Statements 3 and 4 are correct</span></p>"
        },
        {
          "id": 253732,
          "text": "<p><span style=\"font-size:12.0pt;\">All statements are correct</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:16px;\">Evaluate the following statements about the use of Tenecteplase and rtPA in a patient presenting with acute stroke symptoms, including right-sided hemiparesis and aphasia for one hour.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Statements:</strong></span></p><ol><li><span style=\"font-size:16px;\">Tenecteplase should not be administered if the CT scan appears normal.</span></li><li><span style=\"font-size:16px;\">Tenecteplase should not be given before performing an MRI if the CT scan is normal.</span></li><li><span style=\"font-size:16px;\">rtPA can be administered if the patient’s blood pressure is greater than 150/80 mmHg.</span></li><li><span style=\"font-size:16px;\">rtPA can be given to a patient taking warfarin if the INR is 1.4.</span></li></ol>",
      "unique_key": "Q1778848",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384507,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. C) Statements 3 and 4 are correct</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>3. rtPA can be given when BP &gt;150/80 – True:&nbsp;</strong>The contraindication threshold for rtPA administration is a blood pressure greater than 185/110 mmHg. Hence, rtPA can be administered safely if the patient's blood pressure is above 150/80 but below this critical threshold.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>4. rtPA can be given to a patient on warfarin with INR 1.4 – True:&nbsp;</strong>rtPA is considered safe for use in acute ischemic stroke patients on warfarin if the INR is ≤1.7, as the risk of symptomatic intracranial hemorrhage does not increase significantly at this level.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">1. <strong>Tenecteplase is not started if the CT scan is normal – False</strong>: A normal CT scan is actually a requirement for initiating rtPA, as the main reason for performing a CT scan in stroke patients is to exclude intracranial hemorrhage. If no bleeding is detected and the stroke is confirmed to be ischemic, thrombolytic therapy like rtPA or Tenecteplase can be administered.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">4. <strong>Tenecteplase is not started before MRI if the CT scan is normal – False</strong>: In the acute phase of stroke management, MRI is not routinely performed as it delays the initiation of thrombolysis. A non-contrast CT scan is preferred to quickly rule out hemorrhage, facilitating timely treatment.&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Educational Objective:&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">Thrombolytic therapy (rtPA or Tenecteplase) can be initiated in acute ischemic stroke if a CT scan rules out hemorrhage, even if it appears normal. Blood pressure must be managed, but it should only be below 185/110 mmHg for rtPA administration. Warfarin use is not a contraindication if the INR is ≤1.7.</span></p>",
      "correct_choice_id": 253731,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7132,
      "choices": [
        {
          "id": 28496,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hemophilus alters penicillin binding protein sites, hence resistant to ampicillin</span></span></span></p>"
        },
        {
          "id": 28497,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Easier to administer IV ceftriaxone than IV ampicillin</span></span></span></p>"
        },
        {
          "id": 28498,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Cotrimoxazole is the drug of choice, but patient is allergic to sulfa drugs</span></span></span></p>"
        },
        {
          "id": 28499,
          "text": "<p><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hemophilus produces beta lactamase, hence resistant to ampicillin</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 14-month-old boy was diagnosed with Hemophilus influenza meningitis. The initial treatment plan was to start on ampicillin but later was shifted to ceftriaxone. What could be the probable reason? (</span></span>INICET Nov 2021)</p>",
      "unique_key": "Q8119019",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384488,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D. Hemophilus produces beta lactamase, hence resistant to ampicillin &nbsp;</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hemophilus influenzae, particularly some strains, can produce beta-lactamase, an enzyme that breaks down the beta-lactam ring found in penicillins (like ampicillin) and some other antibiotics. This enzymatic activity renders these bacteria resistant to the effects of these antibiotics. Due to the increasing prevalence of beta-lactamase-producing H. influenzae, the use of ampicillin alone is often not recommended for serious infections like meningitis. Ceftriaxone, a third-generation cephalosporin, is a preferred choice as it is more resistant to beta-lactamase and has good central nervous system penetration, which is essential for the treatment of meningitis.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A. Hemophilus alters penicillin-binding protein sites, hence resistant to ampicillin:</span></strong><span style=\"font-size:12.0pt\"> While changes in penicillin-binding proteins can confer resistance to beta-lactam antibiotics, this is not the primary mechanism of resistance in H. influenzae. The major concern is beta-lactamase production.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B. Easier to administer IV ceftriaxone than IV ampicillin:</span></strong><span style=\"font-size:12.0pt\"> While the ease of administration might be a consideration in some cases (ceftriaxone can be given once a day due to its long half-life), the primary concern in this scenario is antibiotic efficacy and resistance patterns, not the convenience of administration.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C. Cotrimoxazole is the drug of choice, but the patient is allergic to sulfa drugs:</span></strong><span style=\"font-size:12.0pt\"> Cotrimoxazole (trimethoprim-sulfamethoxazole) is not the primary drug of choice for H. influenzae meningitis. The first-line treatment is usually a third-generation cephalosporin like ceftriaxone or cefotaxime.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Therefore, the most probable reason for switching from ampicillin to ceftriaxone in this case is the beta-lactamase production by H. influenzae, making it resistant to ampicillin.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The primary reason for switching from ampicillin to ceftriaxone in the treatment of Hemophilus influenzae meningitis is the production of beta-lactamase by H. influenzae, which renders the bacteria resistant to ampicillin. Ceftriaxone is more resistant to beta-lactamase and provides effective CNS penetration, making it a more suitable choice for treating bacterial meningitis.</span></span></span></p>",
      "correct_choice_id": 28499,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3762,
      "choices": [
        {
          "id": 15027,
          "text": "<p><span style=\"font-size:12.0pt;\">Complement mediated cell damage</span></p>"
        },
        {
          "id": 15028,
          "text": "<p><span style=\"font-size:12.0pt;\">Precipitation reaction</span></p>"
        },
        {
          "id": 15029,
          "text": "<p><span style=\"font-size:12.0pt;\">Heterophile antibody test</span></p>"
        },
        {
          "id": 15030,
          "text": "<p><span style=\"font-size:12.0pt;\">Neutralisation reaction</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 25-year-old male with history of fever and enlarged lymph nodes and sore throat was suspected to have infectious mono-nucleosis and was ordered a Paul Bunnel test. Which of the following is the principle of the test? (INICET MAY 2017)</span></p>",
      "unique_key": "Q9016636",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384462,
      "difficulty_level": "beginner",
      "subjects_id": [
        6
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Heterophile antibody test</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Paul Bunnell test is a heterophile antibody reaction test and is used in glandular fever like Infectious mononucleosis.</span></li><li><span style=\"font-size:12.0pt;\">Heterophile antibodies have the ability to <strong>agglutinate RBCs</strong> of different animal species.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Paul Bunnell test uses sheep erythrocytes</strong> for agglutination and Monospot test uses horse erythrocytes for agglutination.</span></li><li><span style=\"font-size:12.0pt;\">In Infectious Mononucleosis<u>, </u><strong><u>IgM heterophile</u> antibodies are detectable for the first 3 months</strong> of infection and they can agglutinate sheep erythrocytes.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Complement mediated cell damage:&nbsp;</strong>This refers to a different mechanism where the complement system causes lysis of cells. It is not related to the principle of the Paul Bunnell test.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Precipitation reaction </strong>uses a soluble antigen to form a precipitate in a solid media when combined with an antibody.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Neutralisation reaction:&nbsp;</strong>Neutralization reactions involve antibodies that neutralize the pathogen, preventing it from infecting cells. This principle does not apply to the Paul Bunnell test.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The Paul Bunnell test is a heterophile antibody test used to diagnose infectious mononucleosis. It detects IgM heterophile antibodies that can agglutinate sheep erythrocytes, which are present during the early stages of the infection.</span></p>",
      "correct_choice_id": 15029,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1209,
      "choices": [
        {
          "id": 4831,
          "text": "<p><span style=\"font-size:12.0pt;\">GI manifestations occurs at a lower radiation dose than bone marrow depression</span></p>"
        },
        {
          "id": 4832,
          "text": "<p><span style=\"font-size:12.0pt;\">Bone marrow suppression appear at doses greater than 1 Gy</span></p>"
        },
        {
          "id": 4833,
          "text": "<p><span style=\"font-size:12.0pt;\">Bone marrow suppression occurs earlier than neurovascular effects</span></p>"
        },
        {
          "id": 4834,
          "text": "<p><span style=\"font-size:12.0pt;\">GI manifestations occur at a lower radiation dose than neurovascular effects</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following statements is false regarding acute radiation syndrome? (AIIMS 2019)</span></p>",
      "unique_key": "Q6105730",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384514,
      "difficulty_level": "intermediate",
      "subjects_id": [
        17
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A. GI manifestations occurs at a lower radiation dose than bone marrow depression</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The statement that gastrointestinal (GI) manifestations occur at a lower radiation dose than bone marrow depression is false. In acute radiation syndrome (ARS), the threshold radiation dose for GI syndrome (8-12 Gy) is higher than that for hematopoietic syndrome, which involves bone marrow suppression (2-8 Gy). Therefore, bone marrow suppression occurs at lower doses compared to GI manifestations.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Bone marrow suppression appears at doses greater than 1 Gy:</strong> This statement is true as bone marrow suppression typically begins to appear at doses around 2 Gy, which is greater than 1 Gy.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Bone marrow suppression occurs earlier than neurovascular effects:</strong> This is true as bone marrow suppression from radiation occurs at lower doses and thus earlier than neurovascular effects, which occur at the highest dose thresholds (12-100 Gy).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. GI manifestations occur at a lower radiation dose than neurovascular effects:</strong> This is true, as GI manifestations appear at a dose range of 8-12 Gy, which is lower than the dose range for neurovascular effects.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Acute Radiation Syndrome (ARS)</strong></span></p><p>&nbsp;</p><ul><li><span style=\"color:black;font-size:12.0pt;\">Occurs with accidental exposure of very high dose radiation</span></li><li><span style=\"color:black;font-size:12.0pt;\">Result of nuclear accidents</span></li></ul><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/23/screenshot-2024-05-23-114356.png\" alt=\"\" width=\"808\" height=\"156\"></p>",
      "correct_choice_id": 4831,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4300,
      "choices": [
        {
          "id": 17177,
          "text": "<p><span style=\"font-size:12.0pt;\">Strongyloides stercoralis</span></p>"
        },
        {
          "id": 17178,
          "text": "<p><span style=\"font-size:12.0pt;\">Ancylostoma duodenale</span></p>"
        },
        {
          "id": 17179,
          "text": "<p><span style=\"font-size:12.0pt;\">Ascaris lumbricoides</span></p>"
        },
        {
          "id": 17180,
          "text": "<p><span style=\"font-size:12.0pt;\">Enterobius vermicularis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The organism with following life cycle is: (INICET MAY 2022)</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/03/31/1-micro-13.jpg\" alt=\"\" width=\"500\" height=\"394\"></span></p>",
      "unique_key": "Q3416082",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384463,
      "difficulty_level": "beginner",
      "subjects_id": [
        6
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Strongyloides stercoralis</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The given life cycle is of Strongyloides stercoralis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Infective form - Filariform larvae</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Natural host – Man</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Mode of infection – <strong>penetration of skin by filariform larvae and autoinfection</strong></span></p><p><br><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/03/31/1-micro-14.jpg\" alt=\"\" width=\"600\" height=\"501\"></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Ancylostoma duodenale</strong> is a hookworm that infects humans through skin penetration by its larvae.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Ascaris lumbricoides</strong> is a roundworm that infects humans through ingestion of contaminated food or water.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Enterobius vermicularis</strong> is a pinworm that infects humans through ingestion of its eggs.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The life cycle of Strongyloides stercoralis involves skin penetration by filariform larvae and autoinfection.</span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/03/31/1-micro-80.jpg\" alt=\"\" width=\"600\" height=\"674\"></p>",
      "correct_choice_id": 17177,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "ImageBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13040,
      "choices": [
        {
          "id": 52122,
          "text": "<p><span style=\"font-size:12.0pt;\">Hereditary spastic quadriplegia</span></p>"
        },
        {
          "id": 52123,
          "text": "<p><span style=\"font-size:12.0pt;\">Subacute combined degeneration</span></p>"
        },
        {
          "id": 52124,
          "text": "<p><span style=\"font-size:12.0pt;\">Neuromyelitis optica</span></p>"
        },
        {
          "id": 52125,
          "text": "<p><span style=\"font-size:12.0pt;\">Multiple sclerosis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 26-year-old female patient presents with 6/60 visual acuity in one eye and 6/18 in the other eye. She has recurrent episodes of diminution of vision which recovers on treatment with steroids. She also has a history of transverse myelitis. What is the most probable diagnosis?</span></p>",
      "unique_key": "Q7322882",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384506,
      "difficulty_level": "intermediate",
      "subjects_id": [
        8
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Neuromyelitis optica</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The most probable diagnosis is neuromyelitis optica (NMO).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">NMO is a demyelinating autoimmune disease that primarily affects the optic nerves and spinal cord. Patients with NMO can present with recurrent episodes of optic neuritis, which can result in decreased visual acuity, as well as myelitis, which can cause weakness, sensory loss, and bladder dysfunction.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The patient's history of recurrent episodes of diminution of vision that recovers on treatment with steroids is consistent with optic neuritis, which is a common presenting feature of NMO. The history of transverse myelitis also supports a diagnosis of NMO, as myelitis is a common feature of the disease.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Management of acute attacks:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">High-dose glucocorticoids</span></li><li><span style=\"font-size:12.0pt;\">Plasma exchange.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Drugs used for prophylaxis against relapses:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Mycophenolate mofetil</span></li><li><span style=\"font-size:12.0pt;\">Rituximab</span></li><li><span style=\"font-size:12.0pt;\">Glucocorticoids</span></li><li><span style=\"font-size:12.0pt;\">Azathioprine.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Hereditary spastic quadriplegia:</strong> This is a genetic disorder affecting motor functions and does not involve optic neuritis or transverse myelitis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Subacute combined degeneration:</strong> Typically associated with vitamin B12 deficiency affecting the spinal cord, but not specifically linked with optic neuritis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Multiple sclerosis (MS):</strong> While MS can present with symptoms similar to NMO, including optic neuritis and spinal cord involvement, the pattern of attacks and the severity of symptoms in the context of transverse myelitis point more specifically to NMO, especially considering the distinct pathophysiology and antibody profiles (e.g., anti-aquaporin-4 antibodies).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Neuromyelitis optica should be considered in patients presenting with recurrent optic neuritis and transverse myelitis, especially when there is a good response to steroid treatment. Distinguishing NMO from multiple sclerosis is crucial, as treatment and prognosis differ significantly between these conditions.</span></p>",
      "correct_choice_id": 52124,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 24773,
      "choices": [
        {
          "id": 99053,
          "text": "<p><span style=\"font-size:11.0pt;\">B12 deficiency</span></p>"
        },
        {
          "id": 99054,
          "text": "<p><span style=\"font-size:11.0pt;\">Normal pressure hydrocephalus</span></p>"
        },
        {
          "id": 99055,
          "text": "<p><span style=\"font-size:11.0pt;\">Lewy body dementia</span></p>"
        },
        {
          "id": 99056,
          "text": "<p><span style=\"font-size:11.0pt;\">Hypothyroidism</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt;\">Which of the following is not a cause of reversible dementia? (INICET MAY 2023)</span></p>",
      "unique_key": "Q8060426",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384497,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C)&nbsp;Lewy body dementia</strong></span></p><p><br><span style=\"font-size:12pt;\">Lewy body dementia is a progressive and irreversible neurodegenerative disorder.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span><br>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. B12 deficiency:</strong> Reversible with supplementation.</span><br>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Normal pressure hydrocephalus:</strong> Reversible with shunting.</span><br>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Hypothyroidism:</strong> Reversible with thyroid hormone replacement.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Lewy body dementia is not a reversible cause of dementia.</span></p>",
      "correct_choice_id": 99055,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16055,
      "choices": [
        {
          "id": 64180,
          "text": "<p>4</p>"
        },
        {
          "id": 64181,
          "text": "<p>3</p>"
        },
        {
          "id": 64182,
          "text": "<p>2</p>"
        },
        {
          "id": 64183,
          "text": "<p>1</p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Third part of vertebral artery is related to which of the following?</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/05/18/ai-13.jpg\" alt=\"\" width=\"300\" height=\"162\"></span></p>",
      "unique_key": "Q7047634",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384500,
      "difficulty_level": "intermediate",
      "subjects_id": [
        3
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C. 2</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The third part of the vertebral artery (V3) is related to the area marked 2, which is the posterior arch of the first cervical vertebra or the atlas.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The given image shows the first cervical vertebra - atlas.</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">The area marked 1 is the posterior tubercle.</span></li><li><span style=\"font-size:12.0pt;\">The area marked 2 is the posterior arch. The superior surface bears a groove for the of vertebral artery and venous plexus immediately behind.</span></li><li><span style=\"font-size:12.0pt;\">The area marked 3 is the superior articular facet.</span></li><li><span style=\"font-size:12.0pt;\">The area marked 4 is the posterior surface of the anterior arch. It gives attachment to the apex of dens from the second cervical vertebra.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The vertebral artery is formed by the first segment of the subclavian artery. It enters the cranium through the foramina of the transverse processes of the cervical vertebrae from C6 to C1. The basilar artery is formed by the union of the vertebral arteries on both sides. In its course. it is divided into four parts:</span></p><p>&nbsp;</p><ol><li><span style=\"font-size:12.0pt;\"><strong>The first part, V1: </strong>begins at its origin from the subclavian artery and ends at its entry into the transverse process of the C6 cervical vertebra. This part is crossed by the inferior thyroid artery on both sides, and thoracic duct on the left side, and the right lymphatic duct on the right side.</span></li><li><span style=\"font-size:12.0pt;\">T<strong>he second part, V2:</strong> is that part of the artery ascending through the foramina in the transverse process of the cervical vertebrae.</span></li><li><span style=\"font-size:12.0pt;\"><strong>The third part, V3</strong>: is curved backward behind the atlas. In this position, it lies in a groove on the posterior arch of the atlas. This part of the artery lies in the suboccipital triangle.</span></li><li><span style=\"font-size:12.0pt;\">T<strong>he fourth part, V4</strong>: pierces the dura and arachnoid mater and unites with the contralateral vertebral artery to form the midline basilar artery at the lower border of pons.</span></li></ol><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/05/18/anat-inicet-nov-2021-10.jpg\" alt=\"\" width=\"500\" height=\"581\"></p>",
      "correct_choice_id": 64182,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7169,
      "choices": [
        {
          "id": 28644,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Topically applied sulfonamide antibacterial</span></span></span></p>"
        },
        {
          "id": 28645,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Topical ocular carbonic anhydrase inhibitor</span></span></span></p>"
        },
        {
          "id": 28646,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Second-generation sulfonylurea</span></span></span></p>"
        },
        {
          "id": 28647,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Opioid receptor agonist</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:left\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dorzolamide is a:&nbsp;</span></span>(INICET NOV 2022)</p>",
      "unique_key": "Q5439806",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384489,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>B. Topical ocular carbonic anhydrase inhibitor</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dorzolamide is a topical ocular carbonic anhydrase inhibitor. It helps in decreasing the rate of formation of aqueous humor in the eye, therefore useful in the management of glaucoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Option A. Topically applied sulfonamide antibacterial</strong> agents include silver sulfadiazine, Mafenide acetate, sulfacetamide etc.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Option C. Second-Generation Sulfonylureas</strong> are oral antidiabetic agents which act via increasing sensitivity of the insulin receptors and stimulate the release of insulin from the pancreas. It is used to manage type-2 diabetes mellitus. It includes Glipizide, Glyburide etc.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Option D. Opioid receptor agonist</strong> is the class of drugs which bind to the opioid receptors in the body. It includes Morphine, Pethidine, Fentanyl etc.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dorzolamide is a topical ocular carbonic anhydrase inhibitor used to reduce intraocular pressure by decreasing the production of aqueous humor, making it effective in the treatment of glaucoma. This distinguishes it from sulfonamide antibacterials, second-generation sulfonylureas, and opioid receptor agonists, which are used for different medical conditions.</span></span></span></p>",
      "correct_choice_id": 28645,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 427,
      "choices": [
        {
          "id": 1704,
          "text": "<p><span style=\"color:black;font-size:12.0pt;\">10</span></p>"
        },
        {
          "id": 1705,
          "text": "<p><span style=\"color:black;font-size:12.0pt;\">5</span></p>"
        },
        {
          "id": 1706,
          "text": "<p><span style=\"color:black;font-size:12.0pt;\">6</span></p>"
        },
        {
          "id": 1707,
          "text": "<p><span style=\"color:black;font-size:12.0pt;\">4</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Which of the marked foramen does the mandibular division of the trigeminal nerve pass through? (</span>AIIMS May 2017)</p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/08/picture4.jpg\" alt=\"\" width=\"300\" height=\"293\"></span></p>",
      "unique_key": "Q1849762",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384529,
      "difficulty_level": "intermediate",
      "subjects_id": [
        3
      ],
      "solution": "<p><span style=\"font-size:11pt;\"><strong>Ans. D. 4</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:11pt;\"><strong>Explanation</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:11pt;\">The mandibular division of the trigeminal nerve passes through the foramen ovale which is marked as 4 in the above image.</span></p><p>&nbsp;</p><p><span style=\"font-size:11pt;\">The foramen ovale is also located in the greater wing of the sphenoid bone.</span></p><p>&nbsp;</p><p><span style=\"font-size:11pt;\">The structure that passes through the foramen ovale is the mandibular nerve (the third division of the trigeminal nerve, Cranial Nerve V3). It carries sensory information from the face and provides motor innervation to the muscles of mastication.</span></p><p>&nbsp;</p><p>Foramen ovale is situated anterior and medial to foramen spinosum, and is larger in size than spinosum.</p><p><br>Structures passing vis foramen ovale can be remembered by the following mnemonic<br>M - Mandibular nerve (3rd division of trigeminal)<br>A - Accessory meningeal artery<br>L - Lesser petrosal nerve<br>E - emissary veins<br>&nbsp;</p><p>&nbsp;</p><p><span style=\"font-size:11pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:11pt;\"><strong>Option A. Foramen Spinosum:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:11pt;\">The foramen spinosum is a small foramen located in the greater wing of the sphenoid bone, near the foramen ovale.</span></li><li><span style=\"font-size:11pt;\">The structure that passes through the foramen spinosum is the middle meningeal artery. This artery supplies blood to the meninges, the protective layers surrounding the brain and spinal cord.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:11pt;\"><strong>Option B. Internal Acoustic Meatus:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:11pt;\">The internal acoustic meatus is located in the petrous part of the temporal bone.</span></li><li><span style=\"font-size:11pt;\">Several important structures pass through this foramen:</span><ol><li><span style=\"font-size:11pt;\"><strong>Facial nerve (Cranial Nerve VII): </strong>It carries motor and sensory fibers related to the muscles of facial expression and taste sensations from the anterior two-thirds of the tongue.</span></li><li><span style=\"font-size:11pt;\">V<strong>estibulocochlear nerve (Cranial Nerve VIII)</strong>: It carries sensory information related to hearing and balance.</span></li></ol></li></ul><p>&nbsp;</p><p><span style=\"font-size:11pt;\"><strong>Option C. Jugular Foramen:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:11pt;\">The jugular foramen is located at the junction of the temporal and occipital bones, near the base of the skull.</span></li><li><span style=\"font-size:11pt;\">Several structures pass through the jugular foramen:</span><ol><li><span style=\"font-size:11pt;\"><strong>Glossopharyngeal nerve (Cranial Nerve IX)</strong>: It carries motor and sensory fibers to the pharynx and taste sensations from the posterior one-third of the tongue.</span></li><li><span style=\"font-size:11pt;\"><strong>Vagus nerve (Cranial Nerve X): </strong>It carries motor and sensory fibers to various organs in the thorax and abdomen and plays a crucial role in autonomic functions.</span></li><li><span style=\"font-size:11pt;\"><strong>Accessory nerve (Cranial Nerve XI)</strong>: It supplies motor fibers to the sternocleidomastoid and trapezius muscles.</span></li><li><span style=\"font-size:11pt;\"><strong>Internal jugular vein:</strong> It is a major vein that drains blood from the brain and parts of the face.</span></li></ol></li></ul><p>&nbsp;</p><p><span style=\"font-size:11.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/08/picture5.jpg\" alt=\"\" width=\"500\" height=\"535\"></span></p>",
      "correct_choice_id": 1707,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13036,
      "choices": [
        {
          "id": 52106,
          "text": "<p><span style=\"font-size:12.0pt;\">Uveitis</span></p>"
        },
        {
          "id": 52107,
          "text": "<p><span style=\"font-size:12.0pt;\">﻿﻿﻿Retinitis pigmentosa</span></p>"
        },
        {
          "id": 52108,
          "text": "<p><span style=\"font-size:12.0pt;\">﻿﻿﻿Keratitis</span></p>"
        },
        {
          "id": 52109,
          "text": "<p><span style=\"font-size:12.0pt;\">﻿﻿﻿Glaucoma</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 6-year-old girl is admitted for evaluation for recurrent seizures. She has a large port-wine stain on her face as shown below. The MRI of the head shows a leptomeningeal angioma. What is the most common ocular manifestation of the underlying condition?</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/29/picture7_xw827Wj.jpg\" alt=\"\" width=\"300\" height=\"280\"></span></p>",
      "unique_key": "Q1875858",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384527,
      "difficulty_level": "intermediate",
      "subjects_id": [
        8
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. D) Glaucoma</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Glaucoma is the most common ocular manifestation of Sturge-Weber syndrome.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Sturge-Weber syndrome (SWS)</strong> is a rare congenital vascular disorder characterized by facial capillary malformation (port-wine stain) and associated capillary-venous malformations affecting the brain and eye.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Mechanisms of glaucoma.</strong>&nbsp;The two main theories regarding the mechanism of glaucoma in eyes with SWS are developmental anomaly of the anterior chamber angle and elevated episcleral venous pressure, each of which leads to aqueous outflow restriction leading to rise in IOP.&nbsp;</span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/04/screenshot-2024-07-04-152605.png\" alt=\"\" width=\"1000\" height=\"296\"></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Uveitis:</strong> This is inflammation of the uvea and not a typical manifestation of SWS.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Retinitis pigmentosa:</strong> This is a group of genetic disorders that affect the retina's ability to respond to light, not commonly associated with SWS.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Keratitis:</strong> Inflammation or infection of the cornea, not linked to SWS.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">In patients with Sturge-Weber syndrome, particularly those presenting with facial port-wine stains and neurological symptoms, glaucoma is a critical ocular manifestation to consider. Regular ophthalmic evaluations are essential due to the high incidence of glaucoma in these patients, focusing on managing elevated IOP to prevent vision loss.</span></p>",
      "correct_choice_id": 52109,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 74879,
      "choices": [
        {
          "id": 298417,
          "text": "<p><span style=\"font-size:16px;\">Mask</span></p>"
        },
        {
          "id": 298418,
          "text": "<p><span style=\"font-size:16px;\">Vaccine</span></p>"
        },
        {
          "id": 298419,
          "text": "<p><span style=\"font-size:16px;\">Ivermectin</span></p>"
        },
        {
          "id": 298420,
          "text": "<p><span style=\"font-size:16px;\">Cough etiquette</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:16px;\">Which of the following is considered ineffective in the prevention of COVID-19? (INICET NOV 2024)</span></p>",
      "unique_key": "Q3962113",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384487,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. C) Ivermectin</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">Ivermectin has been extensively studied during the COVID-19 pandemic but has not demonstrated any proven efficacy in preventing COVID-19 infection. Despite creating headlines during the pandemic period, clinical studies have not provided strong evidence that ivermectin reduces the risk of transmission or acquisition of COVID-19.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option A. Mask:</strong> Wearing masks has been proven to be an effective preventive measure in reducing the transmission of COVID-19 by providing a physical barrier against respiratory droplets.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option B. Vaccine:</strong> Vaccines serve as pre-exposure prophylaxis and have been demonstrated to be effective in preventing severe COVID-19 infection and reducing transmission.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option D. Cough etiquette:</strong> Proper cough etiquette is an important preventive measure that helps reduce the spread of respiratory droplets containing the virus.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">Ivermectin, despite being widely discussed during the pandemic, has not been proven effective in preventing COVID-19 infection, unlike established preventive measures such as masks, vaccines, and proper cough etiquette.</span></p>",
      "correct_choice_id": 298419,
      "solution_audio": null,
      "solution_video": "https://media.cerebellumacademy.com/media/public/question_media/solution/video/74879/INI-CET_NOV_2024_Medicine_Q_-_5.mp4",
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "top",
      "tags": [
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": "https://media.cerebellumacademy.com/media/public/question_media/solution/video/74879/INI-CET_NOV_2024_Medicine_Q_-_5.mp4",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 21930,
      "choices": [
        {
          "id": 87688,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Osteomalacia </span></span></span></p>"
        },
        {
          "id": 87689,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Osteogenesis imperfecta </span></span></span></p>"
        },
        {
          "id": 87690,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Rickets </span></span></span></p>"
        },
        {
          "id": 87691,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Paget&rsquo;s disease </span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A child presented with difficulty in walking. The wrist radiograph is shown below. What is the diagnosis?&nbsp;</span></span></span>(INICET NOVEMBER 2022)</p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/05/screenshot-2024-01-05-103055.jpg\" style=\"height:368px; width:250px\" /></span></span></span></p>",
      "unique_key": "Q7005096",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384470,
      "difficulty_level": "beginner",
      "subjects_id": [
        15
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C. Rickets </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">RICKETS</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Osteoid matrix is secreted at normal rate but the mineralization is decreased (i.e. decrease in mineral apposition rate). </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">This leads to increased osteoid maturation time <strong>(mineralization). </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Osteoid is increased in thickness, volume and total surface area. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Bone tissue throughout skeleton is incompletely calcified and therefore softened. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Rickets&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">refers to condition where it occurs <strong>before closure of growth plates </strong>so that abnormalities of skeletal growth are superimposed.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Pathology:</span></strong></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Osteoid is laid down irregularly with widened osteoid seams and osteoid islets may even persist down into the diaphysis.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The new trabeculae are thin and weak (as bundle of collagen fibers instead of running parallel to Haversian canal, coarse perpendicularly) and with joint loading, the juxta-epiphyseal metaphysis becomes broad and &lsquo;cup-shaped&#39;.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Clinical features:</span></strong></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Generalized muscular hypotonia</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> of an unknown mechanism is observed in most patients with clinical (as opposed to biochemical and radiographic) signs of rickets. </span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Craniotabes</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> (areas of thinning and softening of bones of the skull) manifests early in infants with vitamin D deficiency, although this feature may not be present in infants, especially those born prematurely. </span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">If rickets occurs at a later age, thickening of the skull develops. This produces <strong>frontal bossing</strong> <strong>and delays the closure of the anterior fontanelle</strong>. </span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In the long bones, laying down of uncalcified osteoid at the metaphyses leads to spreading of those areas, producing knobby deformity, which is visualized on radiography as <strong>cupping and flaring of the metaphyses</strong>. </span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/05/screenshot-2024-01-05-103111.jpg\" style=\"height:245px; width:500px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul style=\"list-style-type:circle\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Weight bearing produces deformities such as <strong>bow-legs and knock-knees</strong>. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In the chest, knobby deformities result in the so-called <strong>rachitic rosary</strong> <strong>along the costochondral junctions.</strong> The weakened ribs pulled by muscles also produce flaring over the diaphragm, which is known as <strong>Harrison groove</strong>. The sternum may be pulled into a <strong>pigeon-breast deformity</strong>. </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/05/screenshot-2024-01-05-103123.jpg\" style=\"height:293px; width:250px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul style=\"list-style-type:circle\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In more severe instances in children older than 2 years, vertebral softening leads to kyphoscoliosis. The ends of the long bones demonstrate the same knobby thickening. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">At the ankle, palpation of the tibial malleolus gives the impression of a double epiphysis <strong>(Marfan sign)</strong>. </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/05/screenshot-2024-01-05-103133.jpg\" style=\"height:379px; width:293px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul style=\"list-style-type:circle\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Because the softened long bones may bend, they may fracture on one side of the cortex (i.e., greenstick fracture). </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">X-rays:</span></strong></span></span>\r\n\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Metaphyseal fraying and splaying along with cupping, thickening and widening of growth plate. </span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Bowing of legs and deformities occur at later stages. </span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Investigations: </span></strong></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Serum calcium, phosphate, 25-OH vitamin D are reduced</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">. </span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Increased ALP and diminished urinary excretion of calcium. </span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Treatment:</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Treatment with <strong>vitamin D (400-1000 IU per day) and calcium supplements</strong> are usually effective. </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A. Osteomalacia. </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Often referred to as &quot;<strong>soft bone disease</strong>,&quot; is a metabolic bone disorder characterized by the inadequate mineralization of bone tissue. There is adult onset of bone softening and muscle weakness. This condition results from a deficiency in vitamin D, calcium, or phosphate, weakening and softening bones. Symptoms are non-specific and may include low back and thigh pain, proximal muscle weakness and wasting; Myalgia and arthralgia; Muscle spasms; waddling gait; Spinal, limb, or pelvic&nbsp;deformities; Aching bone pain aggravated by activity and weight-bearing; Increased falls; Hypocalcemic seizures or tetany. <strong>Triradiate pelvis, protrusion acetabular </strong>(acetabulum protrudes into pelvis due to bone softening. When bilateral, it is called as <strong>Otto Pelvis</strong>), <strong>pseudofracture </strong>are seen on x-ray. There is <strong>waddling gait </strong>due to muscular weakness.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/05/screenshot-2024-01-05-103151.jpg\" style=\"height:248px; width:300px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">A. Triradiate pelvis; B. Protrusio acetabuli</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B. Osteogenesis imperfecta. </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It is a genetic disorder of connective tissue determined by <strong>quantitative and qualitative defect in type I collagen formation. </strong>There is alteration in the structural integrity, or a reduction in the total amount of type I collagen. Most common cause of multiple fractures in childhood. It is inherited from a parent in autosomal dominant (AD) fashion, or may occur as spontaneous mutation, or, rarely as autosomal recessive (AR) trait. The defining clinical feature is osteopenia, causing repeated propensity to fracture, generally after minor trauma and often without much pain or swelling. According to the severity of disease, fractures may occur in uterus, at birth, or after birth prior to or after walking age. Lower limb fractures are more common than upper limb. Femur is commonest bone fractured followed by tibia. Hyperlaxity of ligaments, with resultant hypermobility of joint is common. Blue/gray sclera due to uveal pigment visible through thin collagen layer. Deafness due to otosclerosis/pressure on auditory nerve. Dentinogenesis imperfect/crumbling of teeth i.e., deciduous and permanent teeth break easily and become prone to carries. Lower incisors severely affected. Skin becomes thin and translucent. Muscles are hypotonic due to multiple fractures and deformities. Wormian bones (detached portions of primary ossification centers of adjacent membrane bones) are seen in skull X-ray. Ring-shaped epiphysis is seen. Skeleton: White crumpled-bone shaped not maintained. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/05/screenshot-2024-01-05-103206.jpg\" style=\"height:417px; width:250px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D. Paget&rsquo;s disease. </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It is characterized by <strong>excessive disorganized bone turnover, </strong>that encompasses excessive osteoclastic activity initially followed by disorganized excessive new bone formation. <strong>Osteoclast appears larger and irregular </strong>whereas <strong>osteoblast are relatively normal. </strong>The new bone formed is abnormal, very vascular and larger (deforms and fractures) than preexisting bone which leads to cortical widening and contributes to the deformity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/05/screenshot-2024-01-05-103218.jpg\" style=\"height:144px; width:300px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The diagnostic histological feature is irregular area of lamellar bone fitting together like a jigsaw with randomly distributed cement lines. It either occurs in one bone (monostotic) or multiple bones (polyostotic).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/05/screenshot-2024-01-05-103228.jpg\" style=\"height:256px; width:300px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Most people are asymptomatic. </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The sites most commonly involved are <strong>pelvis</strong>, tibia, followed by skull, spine, clavicle and femur. <strong>Pain is most common presenting symptom. </strong>Limb looks bent and feels thick, and skin is unduly warm due to high vascularity. X-ray shows deformity, enlargement or expansion of bone with cortical thickening, coarsening of trabecular markings and lytic and sclerotic changes. Blade of grass lesion is seen.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/05/screenshot-2024-01-05-103243.jpg\" style=\"height:308px; width:300px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The image given in the question shows cupping, fraying and splaying of metaphysis of the distal end of both the radius and ulna, which are characteristic of rickets, alongwith walking difficulty. </span></span></span></li>\r\n</ul>",
      "correct_choice_id": 87690,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "ImageBased",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3490,
      "choices": [
        {
          "id": 13939,
          "text": "<p><span style=\"font-size:12.0pt;\">BSL1</span></p>"
        },
        {
          "id": 13940,
          "text": "<p><span style=\"font-size:12.0pt;\">BSL2</span></p>"
        },
        {
          "id": 13941,
          "text": "<p><span style=\"font-size:12.0pt;\">BSL3</span></p>"
        },
        {
          "id": 13942,
          "text": "<p><span style=\"font-size:12.0pt;\">BSL4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Specimen handling for molecular testing of SARS CoV-2 would require?</span> <span style=\"font-size:10.5pt;\">(</span><span style=\"font-size:12.0pt;\">INICET MAY 2020)</span></p>",
      "unique_key": "Q5924980",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384476,
      "difficulty_level": "intermediate",
      "subjects_id": [
        6
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) BSL2</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Biosafety Level 2 (BSL-2) is required for handling specimens for molecular testing of SARS-CoV-2. BSL-2 facilities are designed for work involving agents that pose moderate hazards to personnel and the environment. This includes diagnostic and other procedures involving the manipulation of known or suspected infectious materials, such as SARS-CoV-2, which causes COVID-19.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">For culturing SARS-CoV-2, which involves growing the virus, higher containment is necessary. Therefore, BSL-3 facilities would be required to ensure higher levels of protection against aerosol transmission and potential infection.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>BSL1</strong>: This level is used for work with well-characterized agents that are not known to consistently cause disease in healthy adults and present minimal potential hazard to laboratory personnel and the environment. It is not suitable for handling SARS-CoV-2 specimens.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>BSL3</strong>: While this level is appropriate for culturing SARS-CoV-2 due to the need for higher containment, it is not required for routine molecular testing.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>BSL4</strong>: This level is reserved for work with dangerous and exotic agents that pose a high risk of aerosol-transmitted laboratory infections and life-threatening disease. It is not necessary for handling SARS-CoV-2 specimens for molecular testing.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>SARS CoV 2 requires BSL-2 or equivalent facilities</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/03/30/1-micro-32.jpg\" alt=\"\" width=\"1000\" height=\"629\"></span></p>",
      "correct_choice_id": 13940,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1936,
      "choices": [
        {
          "id": 7737,
          "text": "<p><span style=\"font-size:12.0pt;\">Alpha ketoglutarate</span></p>"
        },
        {
          "id": 7738,
          "text": "<p><span style=\"font-size:12.0pt;\">Fumarate</span></p>"
        },
        {
          "id": 7739,
          "text": "<p><span style=\"font-size:12.0pt;\">Succinyl CoA</span></p>"
        },
        {
          "id": 7740,
          "text": "<p><span style=\"font-size:12.0pt;\">Malate</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following TCA cycle intermediate is a part of heme metabolism? (</span>AIIMS May 2019)</p>",
      "unique_key": "Q5595789",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384519,
      "difficulty_level": "beginner",
      "subjects_id": [
        1
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Succinyl CoA</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">TCA cycle is truly amphibolic (both catabolic and anabolic) in nature.</span><span style=\"font-size:10.5pt;\"> </span><span style=\"font-size:12.0pt;\">Since various compounds enter into or leave from TCA cycle, it is sometimes called as “<strong>metabolic traffic circle</strong>”.</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\"><strong>Succinyl CoA and Heme Synthesis:</strong></span><ul><li><span style=\"font-size:12.0pt;\"><strong>Function:</strong> Succinyl CoA combines with glycine to form delta-aminolevulinic acid (ALA), which is the first step in the synthesis of heme.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Enzyme Involved:</strong> The enzyme ALA synthase catalyzes this reaction in the mitochondria.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Importance:</strong> Heme is a vital component of hemoglobin, myoglobin, and various cytochromes involved in electron transport and drug metabolism.</span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Alpha Ketoglutarate:</strong></span></p><ul><li><span style=\"font-size:12.0pt;\"><strong>Function:</strong> Precursor for the synthesis of glutamate and subsequently other amino acids.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Relevance:</strong> Not directly involved in heme metabolism.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Fumarate:</strong></span></p><ul><li><span style=\"font-size:12.0pt;\"><strong>Function:</strong> Intermediate in the TCA cycle, involved in the conversion of fumarate to malate.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Relevance:</strong> Not directly involved in heme metabolism.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Malate:</strong></span></p><ul><li><span style=\"font-size:12.0pt;\"><strong>Function:</strong> Intermediate in the TCA cycle, involved in the conversion of malate to oxaloacetate.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Relevance:</strong> Not directly involved in heme metabolism.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Important anabolic reactions</strong> related with citric acid cycle are:</span></p><ol style=\"list-style-type:upper-alpha;\"><li><span style=\"font-size:12.0pt;\"><strong>Oxaloacetate</strong> is the precursor of aspartate</span></li><li><span style=\"font-size:12.0pt;\"><strong>Alpha ketoglutarate</strong> can be made into glutamate</span></li><li><span style=\"font-size:12.0pt;\"><strong>Succinyl CoA</strong> is used for synthesis of heme</span></li><li><span style=\"font-size:12.0pt;\"><strong>Mitochondrial citrate</strong> is transported to cytoplasm, where it is cleaved into acetyl CoA, which then is the <strong>starting point of fatty acid synthesis.</strong></span></li></ol>",
      "correct_choice_id": 7739,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4082,
      "choices": [
        {
          "id": 16307,
          "text": "<p><span style=\"font-size:12.0pt;\">Mycetoma</span></p>"
        },
        {
          "id": 16308,
          "text": "<p><span style=\"font-size:12.0pt;\">Squamous cell carcinoma</span></p>"
        },
        {
          "id": 16309,
          "text": "<p><span style=\"font-size:12.0pt;\">Nocardia</span></p>"
        },
        {
          "id": 16310,
          "text": "<p><span style=\"font-size:12.0pt;\">Sporotrichosis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A farmer presents with a swollen foot and multiple sinuses as shown in the image below. What is the most likely diagnosis? (INICET NOV 2020)</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/03/31/5.jpg\" alt=\"\" width=\"400\" height=\"342\"></span></p>",
      "unique_key": "Q4633171",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384474,
      "difficulty_level": "beginner",
      "subjects_id": [
        6
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Mycetoma</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The most likely diagnosis here is Mycetoma which is caused by <strong>Eumycetoma.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Mycetoma is an uncommon chronic granulomatous infective disease of the skin/dermis and <strong>subcutaneous tissues. “Madura Foot” or “Maduramycosis,” it is caused by true fungi (eumycetoma) or by the filamentous bacteria (actinomycetoma).</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">It is characterized by a <strong>triad of tumefaction, draining sinuses and the presence of colonial grains</strong> in the exudates. It is seen commonly in people who <u>walk barefoot</u>. <u>Eumycetoma is more common in Northern India, while Actinomycetoma is more common in Southern India.</u></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The two main groups of mycetoma are the Actinomycotic and Eumycotic groups. Actinomycetoma is caused by a group of filamentous bacteria which include Nocardia and Streptomyces species. The Nocardia species include Nocardia asteroids, Nocardia braziliensis and Nocardia caviae. The Streptomyces species include Streptomyces madurae, Streptomyces pelletieri and Streptomyces somaliensis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><u>The color of the grains found in the discharge is indicative of the species and helps to initiate appropriate treatment.</u></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The foot is the <u>most commonly affected and the dorsal aspect of the left foot</u> for unexplained reasons is more affected.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The grains are histologically seen as <strong>sulfur granules surrounded by neutrophils </strong>which lead to a purulent tissue reaction containing fibroblasts. This prevents the antibiotic from acting on the micro-organisms, hence the need for debridement in certain cases.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Combined drug therapy is preferred</strong> to a single drug therapy to avoid resistance and any residual infection.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Surgical debridement, followed by prolonged appropriate antibiotic therapy</strong> for several months is required for actinomycetoma while a combination therapy with <u>trimethoprim-sulfamethoxazole</u> (14 mg/kg, twice daily), <u>dapsone</u> (1.5 mg/kg, twice daily) <u>and streptomycin</u> (14 mg/kg) has been used along with <u>Rifampicin </u>for resistant cases.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Squamous cell carcinoma:</strong> Typically presents as a non-healing ulcer or nodule and does not exhibit the characteristic draining sinuses and grains seen in mycetoma.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Nocardia:</strong> Nocardia can cause mycetoma (specifically actinomycetoma), but in the context of the broad diagnosis, mycetoma is the more inclusive and accurate term.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Sporotrichosis:&nbsp;</strong>Caused by <i>Sporothrix schenckii</i>, usually presents with nodular lesions along lymphatic channels rather than multiple sinuses and grains.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Mycetoma is characterized by swelling, draining sinuses, and colonial grains in exudates, and is common among individuals who walk barefoot. The diagnosis is supported by clinical presentation, histology, and the color of the grains. Treatment involves surgical debridement and prolonged antibiotic therapy for actinomycetoma or antifungal therapy for eumycetoma.</span></p>",
      "correct_choice_id": 16307,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14406,
      "choices": [
        {
          "id": 57585,
          "text": "<p><span style=\"font-size:12.0pt;\">Respiratory rate ≥22/min</span></p>"
        },
        {
          "id": 57586,
          "text": "<p><span style=\"font-size:12.0pt;\">Systolic BP &lt; 100 mm Hg</span></p>"
        },
        {
          "id": 57587,
          "text": "<p><span style=\"font-size:12.0pt;\">Altered mental status</span></p>"
        },
        {
          "id": 57588,
          "text": "<p><span style=\"font-size:12.0pt;\">Bilateral absent pupillary reflex</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Identify which of these is not a component of qSOFA? (AIIMS NOV 2019)</span></p>",
      "unique_key": "Q7571949",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384475,
      "difficulty_level": "beginner",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. D) Bilateral absent pupillary reflex</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">qSOFA stands for Quick Sequential Organ Failure Assessment. It is a simplified bedside clinical tool used to quickly assess the risk of organ failure and sepsis in patients. qSOFA includes three Clinical criteria:</span></p><p>&nbsp;</p><ol><li><span style=\"font-size:12.0pt;\">Respiratory Rate ≥ 22/min: A respiratory rate of 22 or higher per minute suggests abnormal breathing and is one of the criteria in qSOFA.</span></li><li><span style=\"font-size:12.0pt;\">Altered Mental Status: Altered mental status, such as confusion or disorientation, is also a component of qSOFA. It reflects the patient's neurological status and helps in evaluating the severity of illness.</span></li><li><span style=\"font-size:12.0pt;\">Systolic Blood Pressure &lt; 100 mm Hg: A systolic blood pressure (BP) less than 100 mm Hg indicates poor perfusion and is another parameter in qSOFA.</span></li></ol><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Derangement in 2 or 3 components carries high mortality.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D: Bilateral absent pupillary reflex</strong>: Not a component of qSOFA. The qSOFA score does not include any criteria related to pupillary reflexes. Bilateral absent pupillary reflex is more relevant to assessing brainstem function or neurological assessment rather than organ failure related to sepsis</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">qSOFA includes three criteria for assessing sepsis risk: respiratory rate ≥ 22/min, systolic BP &lt; 100 mm Hg, and altered mental status. It does not include pupillary reflex assessment.</span></p>",
      "correct_choice_id": 57588,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "CriteriaBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9854,
      "choices": [
        {
          "id": 39382,
          "text": "<p style=\"margin-right:10px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Caspase 1</span></span></span></p>"
        },
        {
          "id": 39383,
          "text": "<p style=\"margin-right:10px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Caspase 8</span></span></span></p>"
        },
        {
          "id": 39384,
          "text": "<p style=\"margin-right:10px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Caspase 9</span></span></span></p>"
        },
        {
          "id": 39385,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Caspase 4</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following caspase binds to Cytochrome C and APAF-1 complex? (AIIMS MAY 2020)</span></span></p>",
      "unique_key": "Q2212603",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384490,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"margin-right:10px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>C) Caspase 9 </strong>&nbsp;</span></span></span></p>\r\n\r\n<p style=\"margin-right:10px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:10px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Caspase 9 binds to Cyt-c and APAF-1 complex.</span></strong></span></span></p>\r\n\r\n<p style=\"margin-right:10px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:10px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Apoptotic stimuli cause the release <em>of <strong>c</strong></em><strong>ytochrome C into the cytosol</strong>. Cytochrome-C binds to a protein called <strong>APAF-1 (apoptosis-activating factor-1)</strong> to form the apoptosome.</span></span></span></p>\r\n\r\n<p style=\"margin-right:10px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:10px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">This complex then binds <strong>caspase-9,</strong> resulting in the activation of other caspases.</span></span></span></p>\r\n\r\n<p style=\"margin-right:10px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/12/984.jpg\" style=\"height:450px; width:630px\" /></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"margin-right:10px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p style=\"margin-right:10px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:10px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A. Caspase 1</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: Involved in the inflammatory response and not in the intrinsic apoptotic pathway.</span></span></span></p>\r\n\r\n<p style=\"margin-right:10px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:10px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B. Caspase 8</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: Associated with the extrinsic apoptotic pathway, activated by death receptors on the cell surface.</span></span></span></p>\r\n\r\n<p style=\"margin-right:10px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:10px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D. Caspase 4</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: Involved in the inflammatory response and not directly related to the intrinsic apoptotic pathway.</span></span></span></p>\r\n\r\n<p style=\"margin-right:10px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:10px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p style=\"margin-right:10px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:10px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Caspase 9 is the initiator caspase in the intrinsic apoptotic pathway and is activated by binding to the cytochrome C and APAF-1 complex (the apoptosome).</span></span></span></p>",
      "correct_choice_id": 39384,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14013,
      "choices": [
        {
          "id": 56013,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A, B, C and D</span></span></span></span></p>"
        },
        {
          "id": 56014,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A and B only</span></span></span></span></p>"
        },
        {
          "id": 56015,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A, B and C</span></span></span></span></p>"
        },
        {
          "id": 56016,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A, B and D</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following are used to stop esophageal variceal bleed? (AIIMS MAY 2020)</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/05/03/ia-97_Kl9G69y.jpg\" style=\"height:487px; width:700px\" /></span></span></span></p>",
      "unique_key": "Q4260122",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384499,
      "difficulty_level": "difficult",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) A, B and C</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;A, B, C can be used to stop esophageal variceal bleed.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;A: Sengstaken Blakemore tube</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;B: Minnesota tube</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;C: Gastric endoscope</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A. Sengstaken Blakemore Tube:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The Sengstaken Blakemore tube is a medical device used for emergency management of esophageal and gastric variceal bleeding by causing balloon tamponade effect, typically associated with liver cirrhosis.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It consists of three lumens: one for inflation of esophageal and gastric balloons each and one for aspiration of gastric contents</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">B. Minnesota Tube:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Similar to SB tube, this has 4 channels, additionally for esophageal aspiration. It is also used for balloon tamponade.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C. Gastric Endoscope:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A gastric endoscope, also known as a gastroscopy or upper endoscopy, is a flexible tube with a camera at the end used for examining the esophagus, stomach, and the beginning of the small intestine.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is primarily a diagnostic tool which can also be used for therapeutic interventions like variceal banding or sclerotherapy.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other option:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">D. Fiberoptic Bronchoscope:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A fiberoptic bronchoscope is a medical instrument used for examining the airways and lungs. It consists of a flexible tube with a light source and a camera that is passed through the nose or mouth into the trachea and bronchi.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is used for diagnostic and therapeutic procedures related to the respiratory system, such as visualizing and obtaining samples from the airways, removing foreign bodies, and managing airway issues.</span></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 56015,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ImageBased",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14345,
      "choices": [
        {
          "id": 57341,
          "text": "<p><span style=\"font-size:12.0pt;\">Hemoglobin falls from 11g% to 10g%</span></p>"
        },
        {
          "id": 57342,
          "text": "<p><span style=\"font-size:12.0pt;\">Extraperitoneal bladder rupture</span></p>"
        },
        {
          "id": 57343,
          "text": "<p><span style=\"font-size:12.0pt;\">Pneumoperitoneum</span></p>"
        },
        {
          "id": 57344,
          "text": "<p><span style=\"font-size:12.0pt;\">Distended gallbladder</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What sign on day 2 would indicate a need for surgery in a patient who was conservatively managed in the ICU after grade 3 splenic trauma? &nbsp;</span><span style=\"font-size:11.0pt;\">(</span><span style=\"font-size:12.0pt;\">INICET MAY 2022)</span></p>",
      "unique_key": "Q8513845",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384492,
      "difficulty_level": "intermediate",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Pneumoperitoneum</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The presence of pneumoperitoneum on imaging would indicate a need for laparotomy as it suggests visceral perforation, which can lead to secondary peritonitis. Conservative management is usually recommended for splenic trauma, and surgical management is reserved for cases of hemodynamic instability or failure to respond to conservative management. Splenic angiography and embolization are also used for non-surgical management. The severity of splenic injury is graded by the AST spleen injury scale, and abdominal CT with intravenous contrast is the preferred investigation. A drop of 1g% of hemoglobin may be a physiological finding, and would not warrant a surgery.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Extraperitoneal bladder rupture can be managed with a urinary catheter, while distended gall bladder is a normal finding if patient has been nil per oral.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Grades of splenic trauma based on the American Association for the Surgery of Trauma (AAST) spleen injury scale:</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/20/screenshot-2024-07-20-123251.png\" alt=\"\" width=\"1000\" height=\"296\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Pneumoperitoneum, the presence of air in the abdominal cavity, is a concerning sign and typically indicates a perforation of the gastrointestinal tract or another abdominal organ. In a patient with grade 3 splenic trauma, the development of pneumoperitoneum suggests a concomitant hollow viscous perforation and would likely necessitate surgery.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Hemoglobin falls from 11g% to 10g%</strong>: A drop in hemoglobin levels can be indicative of ongoing bleeding but may not be an immediate indication for surgery. It would typically be monitored closely, and the need for surgery would depend on the rate of decline and the overall clinical condition of the patient. Typically, a decline by &gt;2g% Hb is suggestive of active bleed and warrants further management.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Extraperitoneal bladder rupture</strong>: While extraperitoneal bladder rupture is a serious condition, it is not directly related to splenic trauma. Its management involves keeping a per urethral Foleys and allowing the rupture to heal.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Distended Gall bladder</strong>: This is a normal physiological finding and does not mandate surgery.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Pneumoperitoneum is the most concerning sign in a patient with grade 3 splenic trauma and would indicate a need for surgery, as it suggests a perforation.</span></p>",
      "correct_choice_id": 57343,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6993,
      "choices": [
        {
          "id": 27940,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Bleomycin</span></span></span></p>"
        },
        {
          "id": 27941,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Doxorubicin</span></span></span></p>"
        },
        {
          "id": 27942,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Vincristine</span></span></span></p>"
        },
        {
          "id": 27943,
          "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Minocycline</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:left\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs can cause flagellated pigmentation of skin? (</span></span><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:11.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">AIIMS MAY 2018)</span></span></p>",
      "unique_key": "Q7779513",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384477,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A. Bleomycin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Bleomycin is the chemotherapeutic drug that is known to cause flagellated hyperpigmentation in the skin. Another side effect of Bleomycin is pulmonary fibrosis.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<h3><span style=\"font-size:13.5pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></h3>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Doxorubicin</span></strong></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This chemotherapeutic agent is known for causing cardiotoxicity and myelosuppression, but it does not typically cause flagellated pigmentation of the skin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vincristine</span></strong></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This drug is associated with neurotoxicity, particularly peripheral neuropathy, but it does not cause flagellated hyperpigmentation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Minocycline</span></strong></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This antibiotic can cause skin pigmentation, but it is not typically flagellated. The pigmentation with minocycline tends to be more diffuse and can affect the skin, nails, and other tissues.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bleomycin is known to cause flagellated hyperpigmentation of the skin as a unique side effect. It can also cause pulmonary fibrosis, making it important to monitor patients for respiratory symptoms during treatment.</span></span></span></p>",
      "correct_choice_id": 27940,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "DiagnosisBased",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 63691,
      "choices": [
        {
          "id": 253969,
          "text": "<p><span style=\"font-size:12.0pt;\">Zinc</span></p>"
        },
        {
          "id": 253970,
          "text": "<p><span style=\"font-size:12.0pt;\">Penicillamine</span></p>"
        },
        {
          "id": 253971,
          "text": "<p><span style=\"font-size:12.0pt;\">Calcium citrate</span></p>"
        },
        {
          "id": 253972,
          "text": "<p><span style=\"font-size:12.0pt;\">Trientine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:16px;\">Which of the following is not given in Wilson's disease?&nbsp;</span></p>",
      "unique_key": "Q6057835",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384498,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. C) Calcium citrate</strong></span></p><p><br><span style=\"font-size:16px;\">Calcium citrate is not part of the treatment regimen for Wilson's disease, as it does not have any role in reducing copper levels in the body.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">The primary treatment approach for Wilson's disease involves medications that help reduce copper accumulation in the body. These include:</span></p><p>&nbsp;</p><ol><li><span style=\"font-size:16px;\"><strong>Chelating Agents</strong>:</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:16px;\"><strong>D-Penicillamine</strong>: It binds to copper, forming a complex that can be excreted through urine. It is the commonly used treatment due to its availability and cost-effectiveness. However, it has side effects such as aplastic anemia, myasthenia gravis, membranous nephropathy, and can worsen neurological symptoms. Supplementation with pyridoxine is recommended since D-penicillamine is a pyridoxine antagonist.</span></li><li><span style=\"font-size:16px;\"><strong>Trientine</strong>: Another chelating agent used in patients who cannot tolerate D-penicillamine.</span></li><li><span style=\"font-size:16px;\"><strong>Tetrathiomolybdate</strong>: This medication is effective in patients with neuropsychiatric symptoms of Wilson's disease.</span><br>&nbsp;</li></ul></li><li><span style=\"font-size:16px;\"><strong>Zinc</strong>:</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:16px;\">Zinc is used as it blocks the absorption of copper in the intestine by inducing metallothionein in enterocytes. It is commonly used as maintenance therapy or as a first-line treatment in pregnant women with Wilson's disease.</span></li></ul></li></ol><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">Calcium citrate is not used in Wilson's disease. Treatment primarily involves chelating agents (like D-penicillamine and trientine) and zinc to manage copper accumulation.</span></p>",
      "correct_choice_id": 253971,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2173,
      "choices": [
        {
          "id": 8681,
          "text": "<p><span style=\"font-size:12.0pt;\">Mutation</span></p>"
        },
        {
          "id": 8682,
          "text": "<p><span style=\"font-size:12.0pt;\">Epigenetics</span></p>"
        },
        {
          "id": 8683,
          "text": "<p><span style=\"font-size:12.0pt;\">Translocation</span></p>"
        },
        {
          "id": 8684,
          "text": "<p><span style=\"font-size:12.0pt;\">Inversion</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following can alter the gene expression by methylation and acetylation but not change the gene sequence? (</span>AIIMS Nov 2017)</p>",
      "unique_key": "Q8940225",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384466,
      "difficulty_level": "beginner",
      "subjects_id": [
        1
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Epigenetics</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Epigenetics refers to the study of changes in gene function that are heritable through cell division (mitotic and meiotic) but do not involve alterations in the DNA sequence. Epigenetic modifications can regulate gene expression by altering the accessibility of transcription factors to the DNA.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Mechanisms of Epigenetics:</strong></span></p><p>&nbsp;</p><ol><li><span style=\"font-size:12.0pt;\"><strong>Histone Acetylation</strong>: The acetylation of specific lysine residues in core histones (H3 and H4) leads to an open chromatin structure, facilitating the access of transcription factors to the DNA and thereby promoting gene transcription.</span></li><li><span style=\"font-size:12.0pt;\"><strong>DNA Methylation</strong>: The addition of methyl groups to cytosine residues, particularly at CpG dinucleotides within gene promoters, leads to chromatin condensation and transcriptional repression.</span></li></ol><p><span style=\"font-size:12.0pt;\">Epigenetic modifications such as methylation and acetylation play crucial roles in regulating gene expression and can influence various biological processes, including development, differentiation, and carcinogenesis, without altering the underlying DNA sequence.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Mutation</strong>: Mutations involve changes in the DNA sequence, such as substitutions, deletions, or insertions, which can affect gene function and expression.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Translocation</strong>: This refers to the rearrangement of parts between nonhomologous chromosomes, which involves changes in the DNA sequence and can disrupt gene function.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Inversion</strong>: An inversion is a chromosomal rearrangement in which a segment of a chromosome is reversed end to end, involving changes in the DNA sequence.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p><span style=\"font-size:10.5pt;\"><strong>&nbsp;</strong></span></p><p><span style=\"font-size:12.0pt;\">Epigenetics involves modifications such as methylation and acetylation that regulate gene expression without changing the DNA sequence, playing a crucial role in various biological processes and diseases.</span></p>",
      "correct_choice_id": 8682,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3442,
      "choices": [
        {
          "id": 13747,
          "text": "<p><span style=\"font-size:12.0pt;\">HBc Ag</span></p>"
        },
        {
          "id": 13748,
          "text": "<p><span style=\"font-size:12.0pt;\">Anti HBs Ab</span></p>"
        },
        {
          "id": 13749,
          "text": "<p><span style=\"font-size:12.0pt;\">Anti HBc Ab</span></p>"
        },
        {
          "id": 13750,
          "text": "<p><span style=\"font-size:12.0pt;\">HBe Ag</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient is diagnosed with Hepatitis B infection. Which of the following markers will always be present in his serum, even during recurrences, or if he develops chronic hepatitis? (INICET MAY 2019)</span></p>",
      "unique_key": "Q9200868",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384484,
      "difficulty_level": "intermediate",
      "subjects_id": [
        6
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Anti Hbc Ab</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The <strong>Anti-HBc antibody</strong> (C) is the marker that will always be present in a patient's serum if they have been exposed to Hepatitis B virus (HBV). This marker is indicative of both past and ongoing infection and remains detectable for life. It indicates a previous or ongoing infection with HBV and is present in both acute and chronic stages of the infection.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. HBc Ag:</strong> Hepatitis B core antigen is typically not detectable in the serum. It is found within the hepatocyte and not usually present in the bloodstream.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Anti HBs Ab:</strong> The antibody against the Hepatitis B surface antigen indicates immunity to HBV, either from past infection or vaccination. It is not present during chronic infection without recovery.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>D</strong>. <strong>HBe Ag</strong>: Hepatitis B e antigen is a marker of active viral replication and high infectivity. It is not present in all stages of infection, especially in chronic carriers where the virus may not be actively replicating.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/22/untitled-186_am92v1d.jpg\" alt=\"\" width=\"1000\" height=\"686\"></p>",
      "correct_choice_id": 13749,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "DiagnosisBased",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11097,
      "choices": [
        {
          "id": 44354,
          "text": "<p><span style=\"font-size:18px;\">1 and 2</span></p>"
        },
        {
          "id": 44355,
          "text": "<p><span style=\"font-size:18px;\">1, 2 and 3</span></p>"
        },
        {
          "id": 44356,
          "text": "<p><span style=\"font-size:18px;\">1, 2, 3, 4</span></p>"
        },
        {
          "id": 44357,
          "text": "<p><span style=\"font-size:18px;\">4 only</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:18px;\"><strong>Which of the provided options align with the depicted equivalence margin graph? [</strong><i><strong>INICET MAY 2021]</strong></i></span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/10/27/psm-pyq-12-1.jpg\" alt=\"\" width=\"500\" height=\"375\"></strong></span></p><p>&nbsp;</p><ol><li><span style=\"font-size:18px;\"><strong>‘A’ represents superiority of new treatment</strong></span></li><li><span style=\"font-size:18px;\"><strong>‘I’ represents Inferiority of new treatment</strong></span></li><li><span style=\"font-size:18px;\"><strong>‘E’ represents Non-inferior treatment</strong></span></li><li><span style=\"font-size:18px;\"><strong>‘C’ is inconclusive</strong></span></li></ol>",
      "unique_key": "Q4187482",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384481,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:18px;\"><strong>Ans. (b) 1, 2 and 3&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\">There are three types of comparators in Randomised Control Trials:</span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>1. Superiority Trial </strong>– New drug is Better than old drug</span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>2. Non-Inferiority Trial </strong>– New drug as good as old drug</span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>3. Equivalence</strong> – New drug same as old drug</span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/10/27/picture2777.jpg\" alt=\"\" width=\"700\" height=\"428\"></span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>Other Option:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>4. 'C' is inconclusive:</strong> This statement is incorrect as per the image. 'C' represents a superior treatment, as it falls well into the \"new treatment better\" region.</span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:18px;\">In equivalence margin graphs for RCTs, 'A' can indicate a superior treatment, 'I' an inferior treatment, and 'E' a non-inferior treatment. 'C' does not represent an inconclusive result; it represents superiority.</span></li></ul>",
      "correct_choice_id": 44355,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12821,
      "choices": [
        {
          "id": 51246,
          "text": "<p><span style=\"font-size:12.0pt;\">Choke/carotid hold</span></p>"
        },
        {
          "id": 51247,
          "text": "<p><span style=\"font-size:12.0pt;\">Carotid sleeper hold</span></p>"
        },
        {
          "id": 51248,
          "text": "<p><span style=\"font-size:12.0pt;\">Hog tie</span></p>"
        },
        {
          "id": 51249,
          "text": "<p><span style=\"font-size:12.0pt;\">Bar arm</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Identify the type of physical restraint given in the picture below: (</span>INICET May 2021)</p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/29/image-16.jpg\" alt=\"\" width=\"300\" height=\"195\"></span></p>",
      "unique_key": "Q5470575",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384491,
      "difficulty_level": "beginner",
      "subjects_id": [
        10
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C. Hog tie</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">This type of physical restraint is called Hog tying. The method involves restraining a prisoner's hands behind his back, restraining his feet and then coupling the hand and feet restraints from the back.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A: Choke/carotid hold:&nbsp;</strong>A choke hold is a grappling hold that critically reduces or prevents either air or blood from passing through the neck of an opponent. It is commonly used in martial arts and law enforcement but is not shown in the image.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B: Carotid sleeper hold:&nbsp;</strong>This hold is a type of choke hold that targets the carotid arteries to induce unconsciousness. It is also used in self-defence and law enforcement but does not match the restraint method shown in the image.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D: Bar arm:&nbsp;</strong>A bar arm restraint involves using the arm to apply pressure to the neck or back, typically in law enforcement. It does not match the method of tying hands and feet together as seen in the image.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Hog tying involves restraining a person’s hands behind their back, restraining their feet, and coupling the hand and feet restraints together from behind, often used as a form of torture or control.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Additional Information</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Torture</strong></span></p><p>&nbsp;</p><ol><li><span style=\"font-size:12.0pt;\"><strong>Wet submarino/ Latina&nbsp; – </strong>suffocation of head in liquids/ dirty liquids</span></li></ol><p style=\"margin-left:24px;\">&nbsp;</p><ol><li><span style=\"font-size:12.0pt;\"><strong>Dry submarino:&nbsp;</strong>Plastic bag around face</span></li></ol><p style=\"margin-left:24px;\">&nbsp;</p><ol><li><span style=\"font-size:12.0pt;\"><strong>Telefono – beating on ear by hands</strong></span></li></ol><p style=\"margin-left:24px;\">&nbsp;</p><ol><li><span style=\"font-size:12.0pt;\"><strong>Falanga (Bastinado): Beating on feet</strong></span></li></ol><p style=\"margin-left:24px;\"><span style=\"font-size:11pt;\"><strong>&nbsp;</strong></span></p><ol><li><span style=\"font-size:12.0pt;\"><strong>Parrot’s perch – </strong>rod placed below knees , upside down , hands tied to rod</span></li></ol><p><br><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/10/13/screenshot-2023-10-13-112432.jpg\" alt=\"\" width=\"300\" height=\"174\"></span><br>&nbsp;</p><p style=\"margin-left:40px;\"><span style=\"font-size:12.0pt;\"><strong>6. Planton – person made to stand for long hours</strong></span></p><p style=\"margin-left:40px;\"><span style=\"font-size:11pt;\"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></span></p><p style=\"margin-left:40px;\"><span style=\"font-size:12.0pt;\"><strong>7. Saw horse – victim sits on sharp object →&nbsp;injury to perineal area</strong></span></p><p style=\"margin-left:40px;\">&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/10/13/whatsapp-image-2023-10-13-at-113825.jpeg\" alt=\"\" width=\"250\" height=\"261\"></strong></span></p><p>&nbsp;</p><p style=\"margin-left:40px;\"><span style=\"font-size:12.0pt;\"><strong>8. Hog tie – </strong>Restraining a prisoner's hands behind his back, restraining his feet and then coupling the hand and feet restraints from the back.</span></p><p style=\"margin-left:40px;\">&nbsp;</p><p style=\"margin-left:40px;\"><span style=\"font-size:12.0pt;\"><strong>9. Ghotna – </strong>wooden log rolled over the legs</span></p><p style=\"margin-left:40px;\">&nbsp;</p><p style=\"margin-left:40px;\"><span style=\"font-size:12.0pt;\"><strong>10. Chepuwa – </strong>wooden log is compressed on legs</span></p><p style=\"margin-left:40px;\">&nbsp;</p><p style=\"margin-left:40px;\"><span style=\"font-size:12.0pt;\"><strong>11. Black slave –</strong> hot metal rod in anus</span></p><p style=\"margin-left:40px;\">&nbsp;</p><p style=\"margin-left:40px;\"><span style=\"font-size:12.0pt;\"><strong>12. Electric cattle prod – </strong>electric current to sensitive parts (nipple, genitalia)</span></p><p>&nbsp;</p>",
      "correct_choice_id": 51248,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "ImageBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6663,
      "choices": [
        {
          "id": 26621,
          "text": "<p><span style=\"font-size:12.0pt;\">In children, equally among males and females</span></p>"
        },
        {
          "id": 26622,
          "text": "<p><span style=\"font-size:12.0pt;\">In adults, equally among males and females</span></p>"
        },
        {
          "id": 26623,
          "text": "<p><span style=\"font-size:12.0pt;\">In adults, occurs more in males than in females</span></p>"
        },
        {
          "id": 26624,
          "text": "<p><span style=\"font-size:12.0pt;\">In children, occurs more in females than in males</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A 14-year-old girl presented with sudden-onset blindness for the past 4 hours. However, on history taking, it is noted that she is not concerned about it. However, she is concerned that her mother passed away recently and that she should have spent more time with her. Physical examination findings are normal. Which of the following is true about the condition?&nbsp;</span>(INICET MAY 2022)</p>",
      "unique_key": "Q5911216",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384459,
      "difficulty_level": "beginner",
      "subjects_id": [
        16
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. D) In children, occurs more in females than in males</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The patient is likely experiencing a conversion disorder, also known as functional neurological symptom disorder. It's characterized by neurological symptoms (such as blindness, paralysis, or seizures) that can't be explained by medical evaluation and are presumably linked to psychological factors. The indifference towards the symptom (e.g., not being concerned about sudden blindness) is termed \"la belle indifférence,\" although this feature is not always present.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">In pediatric populations, females are more commonly affected than males.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Others:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. In children, equally among males and females:</strong> Incorrect. In children, the condition is more common in females.</span></p><p><span style=\"font-size:10.5pt;\">&nbsp;</span></p><p><span style=\"font-size:12.0pt;\"><strong>Option B. In adults, equally among males and females: </strong>Incorrect. In adults, conversion disorder is more common in females than in males.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. In adults, occurs more in males than in females: </strong>Incorrect. The disorder is more common in females than in males in both adults and children.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong>&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Conversion disorder</strong>, also known as <strong>dissociative neurological symptom disorder</strong>, is characterized by neurological symptoms that can't be explained by a medical condition and are believed to arise in response to psychological stressors. The symptoms <strong>do not conform</strong> with <strong>anatomical</strong> and <strong>physiological principles</strong>. The condition is <strong>more common in females</strong> in both pediatric and adult populations.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Reference: Kaplan &amp; Sadock’s Synopsis of Psychiatry, 12th edition, Page No 451-467.</strong></span></p>",
      "correct_choice_id": 26624,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 33323,
      "choices": [
        {
          "id": 133138,
          "text": "<p><span style=\"font-size:12.0pt;\">IVIG</span></p>"
        },
        {
          "id": 133139,
          "text": "<p><span style=\"font-size:12.0pt;\">Aspirin</span></p>"
        },
        {
          "id": 133140,
          "text": "<p><span style=\"font-size:12.0pt;\">Plenty of fluids</span></p>"
        },
        {
          "id": 133141,
          "text": "<p><span style=\"font-size:12.0pt;\">Cephalosporins</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A child came to OPD with fever for 6 days with strawberry tongue, conjunctival congestion, and peeling of skin. What should be the ideal treatment? (INICET NOV 2023)</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/17/screenshot-2024-01-17-120130.jpg\" alt=\"\" width=\"400\" height=\"121\"></span></p>",
      "unique_key": "Q2811367",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384515,
      "difficulty_level": "beginner",
      "subjects_id": [
        13
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) IVIG</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">The constellation of symptoms described (fever, strawberry tongue, conjunctival congestion, and peeling skin) is suggestive of Kawasaki disease. IVIG is a key component of the treatment for Kawasaki disease to reduce the risk of coronary artery abnormalities.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B</strong>. <strong>Aspirin: </strong>This is also a crucial part of the treatment for Kawasaki disease. Aspirin is used in Kawasaki disease to reduce inflammation and the risk of blood clot formation. However, it is often used in conjunction with IVIG.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C</strong>. <strong>Plenty of fluids: </strong>While maintaining hydration is important, fluid administration alone is not the primary treatment for Kawasaki disease. The use of IVIG and aspirin is more specific to address the underlying inflammatory process.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D</strong>. <strong>Cephalosporins: </strong>Cephalosporins are antibiotics and are not the appropriate treatment for Kawasaki disease, which is not caused by a bacterial infection.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:&nbsp;</strong></span><span style=\"font-size:11pt;\">&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:11pt;\"><strong>Fever + 4 out of 5 below = Classic Kawasaki</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:11pt;\"><strong><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-06-20%20122250.png\" width=\"1209\" height=\"422\"></strong></span></p>",
      "correct_choice_id": 133138,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "ImageBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 24720,
      "choices": [
        {
          "id": 98841,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Acarbose </span></span></span></p>"
        },
        {
          "id": 98842,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Canagliflozin </span></span></span></p>"
        },
        {
          "id": 98843,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Linagliptin </span></span></span></p>"
        },
        {
          "id": 98844,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Liraglutide</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">An individual with type 2 diabetes mellitus was prescribed a medication that lowered their HbA1C levels from 7.6 to 6.7. Subsequently, the person began experiencing discomfort characterized by itching in the vulvovaginal region. What is the probable medication that was initiated for this individual?&nbsp;</span></span></span>(INICET May 2023)</p>",
      "unique_key": "Q3589247",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384496,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B. Canagliflozin </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The patient complaining of itching in genital region after consuming a drug to lower down HbA1C levels is likely pointing to urogenital infection, which is a side effect associated with Canagliflozin (SGLT2 inhibitor).</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">SGLT-2 INHIBITORS</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Glucose is freely filtered by glomerulus but the clearance of glucose in urine is negligible.</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Because the reabsorption takes place in proximal tubule by sodium glucose transporter (SGLT-2)</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">SGLT-2 inhibitors stop the reabsorption of glucose in PT resulting in glucosuria.</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Most common side effect of SGLT-2 Inhibitors is Urinary Tract infections (urosepsis) and genital Tract infections. (e.g., Fournier&rsquo;s gangrene)</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">If gliflozins are taken by type 1 diabetes patients, it controls blood sugar level and makes it normal and then if the patients stop taking insulin, it will result in Ketoacidosis (as type 1 diabetes is characterized by complete deficiency of insulin)</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">SLGT-2 inhibitors provide cardiovascular benefits. These are approved for treatment of CHF.</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Drugs are. </span></strong></span></span>\r\n\t<ul>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Canagliflozin </span></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Dapagliflozin </span></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Empagliflozin </span></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ertugliflozin </span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A. Acarbose</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: This is an alpha-glucosidase inhibitor that primarily acts in the intestine to slow down the breakdown of complex carbohydrates. It is not usually associated with vulvovaginal itching.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">C. Linagliptin</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: A DPP-4 inhibitor, Linagliptin is not typically associated with vulvovaginal itching or infections.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">D. Liraglutide</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: This GLP-1 agonist is more commonly associated with gastrointestinal side effects rather than vulvovaginal itching.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Canagliflozin</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> is an SGLT2 inhibitor that lowers blood sugar by causing more glucose to be excreted in the urine. It is known for causing genitourinary infections, including vulvovaginal candidiasis, which can result in symptoms like itching and discomfort.</span></span></span></p>",
      "correct_choice_id": 98842,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1292,
      "choices": [
        {
          "id": 5163,
          "text": "<p><span style=\"font-size:12.0pt;\">Bochdalek hernia</span></p>"
        },
        {
          "id": 5164,
          "text": "<p><span style=\"font-size:12.0pt;\">Morgagni hernia</span></p>"
        },
        {
          "id": 5165,
          "text": "<p><span style=\"font-size:12.0pt;\">Hiatal hernia</span></p>"
        },
        {
          "id": 5166,
          "text": "<p><span style=\"font-size:12.0pt;\">Eventration of diaphragm</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A 25-year-old male presented with mild intermittent upper abdominal pain. X-ray is given below. What is the diagnosis? (INICET NOV 2021)</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/03/26/untitled-169.jpg\" alt=\"\" width=\"300\" height=\"345\"></span></p>",
      "unique_key": "Q5595350",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384523,
      "difficulty_level": "intermediate",
      "subjects_id": [
        17
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Hiatal hernia</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Retrocardiac air fluid level is seen on CXR which is suggestive of a hiatal hernia. It is defined as the displacement through esophageal hiatus of GE junction or other parts of the stomach into the thoracic cavity</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/23/screenshot-2024-05-23-152745.png\" alt=\"\" width=\"868\" height=\"403\"></span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>IOC for hiatal hernia:</strong> Contrast enhanced CT + oral contrast (Iohexol most commonly) (to determine obstruction/ Volvulus)</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Bochdalek hernia: </strong>This is a congenital diaphragmatic hernia typically occurring at the posterolateral part of the diaphragm, not associated with the retrocardiac region.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Morgagni hernia: </strong>Another type of congenital diaphragmatic hernia that occurs anteriorly at the sternocostal triangles, not retrocardiac.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Eventration of diaphragm: </strong>Involves an abnormal elevation of the diaphragm muscle, not typically presenting as an air-fluid level in the retrocardiac area.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Hiatal hernia can be diagnosed on plain chest X-ray when an air-fluid level is visible in the retrocardiac area, indicating herniation of stomach contents into the thorax through the esophageal hiatus. Contrast-enhanced CT with oral contrast is the imaging of choice for further evaluation, particularly to assess for any complications like obstruction or volvulus.</span></p>",
      "correct_choice_id": 5165,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "ImageBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 74673,
      "choices": [
        {
          "id": 297605,
          "text": "<p><span style=\"font-size:16px;\">BERA</span></p>"
        },
        {
          "id": 297606,
          "text": "<p><span style=\"font-size:16px;\">PTA</span></p>"
        },
        {
          "id": 297607,
          "text": "<p><span style=\"font-size:16px;\">OAE (Otoacoustic Emissions)</span></p>"
        },
        {
          "id": 297608,
          "text": "<p><span style=\"font-size:16px;\">Impedance</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:16px;\">Which of the following is the first investigation in newborn for audiological assessment? (INICET NOV 2024)</span></p>",
      "unique_key": "Q5795919",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384512,
      "difficulty_level": "intermediate",
      "subjects_id": [
        9
      ],
      "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. C) OAE (Otoacoustic Emissions)</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">OAE is the first choice for newborn hearing screening because:</span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:16px;\">It is a simple, quick, and non-invasive test</span></li><li><span style=\"font-size:16px;\">Can be done with a portable device</span></li><li><span style=\"font-size:16px;\">Involves placing a probe in the infant's ear that sends sound stimulus and captures emissions from outer hair cells</span></li><li><span style=\"font-size:16px;\">If result is \"pass\", indicates normal hearing</span></li><li><span style=\"font-size:16px;\">If result is \"refer\", then BERA is done as the next step</span></li><li><span style=\"font-size:16px;\">Tests the integrity of outer hair cells in the cochlea</span></li><li><span style=\"font-size:16px;\">Can be performed while baby is sleeping or quiet</span></li></ul><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/image_FBomM5G.png\" width=\"738\" height=\"142\"></p><p><span style=\"font-size:16px;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option A. BERA (Brainstem Evoked Response Audiometry):</strong> Though essential for newborn screening, it is more complex and time-consuming than OAE. It is used as a second-line test if OAE results are abnormal.</span></p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/image_pwXp8X8.png\" width=\"617\" height=\"383\"></p><p><span style=\"font-size:16px;\"><strong>Option B. PTA (Pure Tone Audiometry):</strong> Not suitable for newborns as it requires active participation and response from the subject, which newborns cannot provide.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option D. Impedance:</strong> Not appropriate as first-line screening in newborns as it primarily tests middle ear function and requires some cooperation from the subject.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Educational Objective:</strong>&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">OAE is the first-line screening test for newborn hearing assessment due to its simplicity, speed, and non-invasive nature.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Newborn screening of hearing:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:16px;\">Here we test otoacoustic emissions (OAE) and brainstem evoked response audiometry (BERA).</span></li><li><span style=\"font-size:16px;\">Outer hair cells in cochlea emit these very low intensity sounds (OAE) &amp; they can be collected by a microphone kept in EAC.</span></li><li><span style=\"font-size:16px;\">Normal OAE means cochlear hair cells are functioning normally and cochlea is normally functioning.</span></li><li><span style=\"font-size:16px;\">BERA tests the integrity of auditory nerve (auditory pathway from cochlea to brain). It is an objective test.</span><ul><li><span style=\"font-size:16px;\">Here we give a sound stimulus and check the electrical potentials that arise along the auditory pathway from cochlear nerve to brain.</span></li><li><span style=\"font-size:16px;\">Wave V is most prominent in BERA that corresponds to lateral lemniscus.</span></li><li><span style=\"font-size:16px;\">It is a non-invasive procedure. It is also an objective test (whereas PTA is a subjective test = result depends on the responses given by patient/subject).</span></li></ul></li><li><span style=\"font-size:16px;\">Normal BERA means the cochlear nerve is intact and conducting sound impulses from cochlea to brain.</span></li><li><span style=\"font-size:16px;\">So, normal OAE and BERA will indicate an almost normal hearing pathway, hence used in newborn screening.</span></li><li><span style=\"font-size:16px;\">BERA is also used to check malingerers (people those who pretend deaf).</span></li></ul>",
      "correct_choice_id": 297607,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5979,
      "choices": [
        {
          "id": 23886,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Measure CA 125 levels</span></span></span></p>"
        },
        {
          "id": 23887,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Follow up after 6 weeks</span></span></span></p>"
        },
        {
          "id": 23888,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Laparoscopy</span></span></span></p>"
        },
        {
          "id": 23889,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CT pelvis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 26-year-old woman who has had 2 children through normal delivery presents with a dull aching pain over the abdomen, with irregular menses. Per vaginal examination revealed a mass felt through the posterior fornix. A USG showed a clear ovarian cyst of size 5 x 5 cm. What is the next best step?&nbsp;</span></span>(INICET NOV 2021)</p>",
      "unique_key": "Q8279405",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384465,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Follow up after 6 weeks</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A clear ovarian cyst with minimal symptoms and size less than 8 cm in a woman of reproductive age group is most likely a functional ovarian cyst. The next best step in the management of this case is to follow up after 6-12 weeks and perform a repeat USG.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Key Points:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Functional Ovarian Cyst:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> In reproductive-aged women, a clear ovarian cyst less than 8 cm is likely functional.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Follow-Up:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The recommended management is to follow up after 6-12 weeks with a repeat ultrasound to check if the cyst resolves on its own.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Indications for Further Intervention:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Surgical treatment is warranted if there are worrying features, the cyst is greater than 8 cm, there are significant symptoms, or CA-125 levels are raised.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Measure CA 125 levels:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> CA 125 is a marker for epithelial ovarian tumors and is more relevant in postmenopausal women. It has limited role in premenopausal women with clear, simple cysts.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Laparoscopy:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Surgical intervention such as laparoscopy is not immediately necessary for a 5 cm cyst unless there are concerning features or persistence after follow-up.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. CT pelvis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> CT scan is not typically indicated for initial assessment of a simple ovarian cyst detected on ultrasound.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Additional information:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">OC Pills:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Oral contraceptive pills have not been proven effective in treating simple ovarian cysts, though they are often used.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Simple Ovarian Cysts:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Any simple ovarian cyst less than 5 cm without symptoms can be left alone.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For a reproductive-aged woman with a clear ovarian cyst less than 8 cm and minimal symptoms, the best approach is to follow up with a repeat ultrasound after 6-12 weeks, rather than immediate intervention.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: RCOG greentop guideline number 62 , Williams textbook of gynecology 3<sup>rd</sup> edition pg217</span></strong></span></span></p>",
      "correct_choice_id": 23887,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 44841,
      "choices": [
        {
          "id": 179011,
          "text": "<p><span style=\"font-size:12pt;\">Sugammadex</span></p>"
        },
        {
          "id": 179012,
          "text": "<p><span style=\"font-size:12pt;\">Neostigmine</span></p>"
        },
        {
          "id": 179013,
          "text": "<p><span style=\"font-size:12pt;\">Edrophonium</span></p>"
        },
        {
          "id": 179014,
          "text": "<p><span style=\"font-size:12pt;\">Atropine</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">A 60-year-old male patient underwent surgery under general anaesthesia. Rocuronium was used as a muscle relaxant during the procedure. After the surgery, the patient has not regained muscle function, indicating prolonged muscle paralysis. The medical team needs to reverse the effects of rocuronium quickly to ensure patient safety and recovery. Which of the following can result in the fastest reversal? (INICET MAY 2024)</span></p>",
      "unique_key": "Q2279563",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384521,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A) Sugammadex</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Sugammadex is a specific reversal agent for aminosteroid neuromuscular blocking agents such as rocuronium and vecuronium. It works by encapsulating the rocuronium molecules, rendering them inactive, and thus rapidly reversing the neuromuscular blockade. Sugammadex provides the fastest and most effective reversal of rocuronium-induced paralysis.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option</strong>&nbsp;<strong>B.</strong>&nbsp;<strong>Neostigmine</strong>: Neostigmine is an acetylcholinesterase inhibitor that increases the levels of acetylcholine at the neuromuscular junction, competing with rocuronium. While effective, it is slower and less specific than sugammadex and can have more side effects.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option</strong>&nbsp;<strong>C.</strong>&nbsp;<strong>Edrophonium</strong>: Edrophonium is also an acetylcholinesterase inhibitor but is less commonly used compared to neostigmine for reversing neuromuscular blockade. It is generally faster than neostigmine but still not as rapid or effective as sugammadex for rocuronium reversal.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option</strong>&nbsp;<strong>D.</strong>&nbsp;<strong>Atropine</strong>: Atropine is not used for reversing neuromuscular blockade. It is an anticholinergic agent primarily used to counteract the muscarinic side effects of acetylcholinesterase inhibitors like neostigmine and edrophonium, such as bradycardia. It does not reverse muscle paralysis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">In summary, sugammadex is the most effective and fastest-acting agent for reversing the effects of rocuronium, making it the best choice in this clinical scenario.</span></p>",
      "correct_choice_id": 179011,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2169,
      "choices": [
        {
          "id": 8665,
          "text": "<p><span style=\"font-size:12.0pt;\">It maintains renal output</span></p>"
        },
        {
          "id": 8666,
          "text": "<p><span style=\"font-size:12.0pt;\">It scavenges nitrogen</span></p>"
        },
        {
          "id": 8667,
          "text": "<p><span style=\"font-size:12.0pt;\">It maintains energy production</span></p>"
        },
        {
          "id": 8668,
          "text": "<p><span style=\"font-size:12.0pt;\">It activates enzymes</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is the reason for using phenylbutyrate in urea cycle disorders? (</span>AIIMS Nov 2017)</p>",
      "unique_key": "Q5678072",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384508,
      "difficulty_level": "beginner",
      "subjects_id": [
        1
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) It scavenges nitrogen</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">In urea cycle disorders ammonia cannot be converted to urea, but alternatively can be converted to glutamine and glycine. <strong>Ammonia scavengers phenylbutyrate and sodium benzoate</strong> react with glutamine and glycine and consequently remove excess of ammonia. Phenylglutamine and hippurate are excreted in urine.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Phenylbutyrate is metabolized into phenylacetate, which conjugates with glutamine to form phenylacetylglutamine. Similarly, sodium benzoate conjugates with glycine to form hippurate. Both phenylacetylglutamine and hippurate are excreted in the urine, thereby reducing the levels of ammonia in the body.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>It maintains renal output</strong>: While phenylbutyrate and sodium benzoate are excreted in the urine, their primary function is not to maintain renal output but to remove excess ammonia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>It maintains energy production</strong>: Phenylbutyrate does not directly impact energy production. Its primary role is to help remove excess ammonia from the body.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>It activates enzymes</strong>: Phenylbutyrate does not activate enzymes. Instead, it works by conjugating with amino acids to facilitate the removal of ammonia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Phenylbutyrate is used in urea cycle disorders to scavenge nitrogen by reacting with glutamine, converting excess ammonia into phenylacetylglutamine, which is then excreted in the urine.</span></p>",
      "correct_choice_id": 8666,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14029,
      "choices": [
        {
          "id": 56077,
          "text": "<p><span style=\"font-size:12.0pt;\">Ureteral stenting</span></p>"
        },
        {
          "id": 56078,
          "text": "<p><span style=\"font-size:12.0pt;\">Surgical repair and exploration</span></p>"
        },
        {
          "id": 56079,
          "text": "<p><span style=\"font-size:12.0pt;\">Observation</span></p>"
        },
        {
          "id": 56080,
          "text": "<p><span style=\"font-size:12.0pt;\">Percutaneous drainage</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A trauma patient suffered a renal laceration with urine extravasation. He was managed conservatively.</span> <span style=\"font-size:12.0pt;\">However, after a few days, he presented with a urinoma. The next best management for this patient would be? (AIIMS MAY 2017)</span></p>",
      "unique_key": "Q4712854",
      "question_audio": null,
      "question_video": null,
      "map_id": 35384478,
      "difficulty_level": "difficult",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Ureteral stenting</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The patient in the given question has renal laceration with urine extravasation, which classifies as grade 4 renal injury.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Ureteral stenting is a minimally invasive procedure that can help alleviate the obstruction and promote urine drainage, reducing the risk of infection and other complications associated with urinomas</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Ureteral stenting involves the placement of a stent into the ureter to facilitate drainage of urine from the renal pelvis to the bladder. In the context of a urinoma, this can help alleviate the obstruction or urine accumulation, providing relief and preventing further complications. It is similar to placement of CBD stent via ERCP in cystic duct leak.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Surgical Repair and Exploration:&nbsp;</strong>Surgical repair and exploration may be considered if there is a significant structural or anatomical issue contributing to the urinoma that cannot be resolved through less invasive methods.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Observation:&nbsp;</strong>Observation alone may not be sufficient if the urinoma is causing discomfort, pain, or complications. It's crucial to address the urinoma promptly.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Percutaneous Drainage:&nbsp;</strong>Percutaneous drainage may be an option, but ureteral stenting is a more specific approach for managing urinomas resulting from ureteral obstruction.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">A urinoma is a collection of urine that has leaked from the urinary tract and has accumulated outside its normal anatomical location. This condition typically occurs due to trauma, injury, or obstruction in the urinary system.</span></p><p>&nbsp;</p><ol><li><span style=\"font-size:12.0pt;\"><strong>Causes:&nbsp;</strong>Urinomas are usually caused by trauma, such as blunt abdominal or pelvic trauma, that leads to injury to the urinary collecting system. They can also result from urinary tract obstruction, infections, or surgical complications.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Symptoms:&nbsp;</strong>Common symptoms of a urinoma may include abdominal or flank pain, fever, and swelling in the affected area. In some cases, urinomas may be asymptomatic and discovered incidentally during imaging studies.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Diagnosis:&nbsp;</strong>Diagnosis involves a combination of medical history, physical examination, and imaging studies, such as ultrasound, CT scans, or MRI, to visualize the urinoma and determine its size and location.</span></li></ol><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">A persistent urinoma (a mass formed by encapsulated extravasated urine) should be managed with the placement of an internal ureteral stent.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Patients not cured by ureteral stenting may require percutaneous nephrostomy or transcutaneous drainage.</span></p>",
      "correct_choice_id": 56077,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}